

Table 19.1  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2009 With up to Five Joinpoints, 1992-2009 With up to Three Joinpoints,  
Both Sexes by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC <sup>d</sup>	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2000-09	2005-09
<u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2009</u>														
All Races	1975-91	3.6*	1991-09	0.6*									0.6*	0.6*
White	1975-91	3.7*	1991-09	0.6*									0.6*	0.6*
Black	1975-93	4.8*	1993-09	0.7									0.7	0.7
<u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2009</u>														
All Races	1992-09	0.5*											0.5*	0.5*
White	1992-09	0.5*											0.5*	0.5*
Black	1992-97	3.9*	1997-00	-4.0	2000-04	4.2	2004-09	-1.7					0.9	-1.7
<u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2009</u>														
All Races	1975-91	3.7*	1991-09	0.5*									0.5*	0.5*
White	1975-90	3.8*	1990-04	0.8*	2004-09	-0.6							0.0	-0.6
Black	1975-94	4.6*	1994-09	0.3									0.3	0.3
<u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2009</u>														
All Races	1992-09	0.4*											0.4*	0.4*
White	1992-09	0.4*											0.4*	0.4*
White NH <sup>ef</sup>	1992-09	0.5*											0.5*	0.5*
Black	1992-97	3.8*	1997-00	-4.1	2000-04	4.1	2004-09	-2.3*					0.5	-2.3*
Black NH <sup>ef</sup>	1992-97	3.7*	1997-00	-4.0	2000-04	4.0	2004-09	-2.2*					0.5	-2.2*
API <sup>e</sup>	1992-09	0.2											0.2	0.2
AI/AN <sup>eg</sup>	1992-09	2.8*											2.8*	2.8*
Hispanic <sup>f</sup>	1992-09	0.3*											0.3*	0.3*
<u>U.S. Cancer Mortality<sup>c</sup>, 1975-2009</u>														
All Races	1975-91	2.5*	1991-97	1.6*	1997-09	-3.0*							-3.0*	-3.0*
White	1975-91	2.5*	1991-97	1.6*	1997-09	-3.0*							-3.0*	-3.0*
Black	1975-96	2.7*	1996-09	-2.6*									-2.6*	-2.6*
<u>U.S. Cancer Mortality<sup>c</sup>, 1992-2009</u>														
All Races	1992-97	1.6*	1997-09	-3.0*									-3.0*	-3.0*
White	1992-97	1.6*	1997-09	-3.0*									-3.0*	-3.0*
White NH <sup>ef</sup>	1992-97	1.8*	1997-09	-2.9*									-2.9*	-2.9*
Black	1992-97	1.9	1997-09	-2.8*									-2.8*	-2.8*
Black NH <sup>ef</sup>	1992-96	3.7	1996-09	-2.4*									-2.4*	-2.4*
API <sup>e</sup>	1992-09	-2.1*											-2.1*	-2.1*
AI/AN <sup>eg</sup>	1992-09	0.0											0.0	0.0
Hispanic <sup>f</sup>	1992-96	3.8	1996-09	-2.7*									-2.7*	-2.7*

Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from CT, DC, ME, MD, MN, NH, NY, ND, SC, OK and VT.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.2  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2009 With up to Five Joinpoints, 1992-2009 With up to Three Joinpoints,  
Males by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC <sup>d</sup>	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2000-09	2005-09
<u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2009</u>														
All Races	1975-91	4.2*	1991-09	0.4*									0.4*	0.4*
White	1975-90	4.5*	1990-09	0.5*									0.5*	0.5*
Black	1975-94	5.5*	1994-09	-0.5									-0.5	-0.5
<u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2009</u>														
All Races	1992-09	0.2											0.2	0.2
White	1992-09	0.3*											0.3*	0.3*
Black	1992-09	-0.1											-0.1	-0.1
<u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2009</u>														
All Races	1975-91	4.2*	1991-09	0.3*									0.3*	0.3*
White	1975-90	4.5*	1990-09	0.4*									0.4*	0.4*
Black	1975-94	5.5*	1994-09	-0.7									-0.7	-0.7
<u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2009</u>														
All Races	1992-09	0.1											0.1	0.1
White	1992-09	0.1											0.1	0.1
White NH <sup>ef</sup>	1992-09	0.3*											0.3*	0.3*
Black	1992-09	-0.3											-0.3	-0.3
Black NH <sup>ef</sup>	1992-09	-0.3											-0.3	-0.3
API <sup>e</sup>	1992-09	0.1											0.1	0.1
AI/AN <sup>eg</sup>	1992-09	2.2											2.2	2.2
Hispanic <sup>f</sup>	1992-09	-0.2											-0.2	-0.2
<u>U.S. Cancer Mortality<sup>c</sup>, 1975-2009</u>														
All Races	1975-91	2.7*	1991-97	1.5*	1997-09	-2.7*							-2.7*	-2.7*
White	1975-96	2.5*	1996-09	-2.6*									-2.6*	-2.6*
Black	1975-96	2.7*	1996-09	-2.6*									-2.6*	-2.6*
<u>U.S. Cancer Mortality<sup>c</sup>, 1992-2009</u>														
All Races	1992-97	1.5*	1997-09	-2.7*									-2.7*	-2.7*
White	1992-97	1.5*	1997-09	-2.7*									-2.7*	-2.7*
White NH <sup>ef</sup>	1992-97	1.9*	1997-09	-2.6*									-2.6*	-2.6*
Black	1992-09	-1.8*											-1.8*	-1.8*
Black NH <sup>ef</sup>	1992-09	-1.6*											-1.6*	-1.6*
API <sup>e</sup>	1992-09	-2.3*											-2.3*	-2.3*
AI/AN <sup>eg</sup>	1992-09	-1.1											-1.1	-1.1
Hispanic <sup>f</sup>	1992-96	3.5	1996-09	-3.0*									-3.0*	-3.0*

Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from CT, DC, ME, MD, MN, NH, NY, ND, SC, OK and VT.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.3  
Non-Hodgkin Lymphoma

Trends in SEER Incidence<sup>ab</sup> and U.S. Mortality<sup>c</sup> Using the Joinpoint Regression Program,  
1975-2009 With up to Five Joinpoints, 1992-2009 With up to Three Joinpoints,  
Females by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC <sup>d</sup>	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2000-09	2005-09
<u>SEER 9 Delay-Adjusted Incidence<sup>a</sup>, 1975-2009</u>														
All Races	1975-90	2.8*	1990-04	1.3*	2004-09	-0.4							0.4	-0.4
White	1975-88	3.1*	1988-04	1.4*	2004-09	-0.8							0.2	-0.8
Black	1975-09	2.5*											2.5*	2.5*
<u>SEER 13 Delay-Adjusted Incidence<sup>b</sup>, 1992-2009</u>														
All Races	1992-03	1.4*	2003-09	-0.1									0.4	-0.1
White	1992-04	1.3*	2004-09	-0.3									0.4	-0.3
Black	1992-98	5.5*	1998-09	0.7									0.7	0.7
<u>SEER 9 Observed Incidence<sup>a</sup>, 1975-2009</u>														
All Races	1975-90	2.8*	1990-04	1.2*	2004-09	-0.8							0.1	-0.8
White	1975-88	3.1*	1988-04	1.4*	2004-09	-1.3							-0.1	-1.3
Black	1975-09	2.4*											2.4*	2.4*
<u>SEER 13 Observed Incidence<sup>b</sup>, 1992-2009</u>														
All Races	1992-03	1.3*	2003-09	-0.5									0.1	-0.5
White	1992-04	1.2*	2004-09	-0.8									0.1	-0.8
White NH <sup>ef</sup>	1992-04	1.4*	2004-09	-1.1									0.0	-1.1
Black	1992-98	5.6*	1998-09	0.4									0.4	0.4
Black NH <sup>ef</sup>	1992-98	5.4*	1998-09	0.5									0.5	0.5
API <sup>e</sup>	1992-09	0.5											0.5	0.5
AI/AN <sup>eg</sup>	1992-09	3.2*											3.2*	3.2*
Hispanic <sup>f</sup>	1992-09	1.0*											1.0*	1.0*
<u>U.S. Cancer Mortality<sup>c</sup>, 1975-2009</u>														
All Races	1975-94	2.2*	1994-97	1.0	1997-09	-3.4*							-3.4*	-3.4*
White	1975-88	2.4*	1988-97	1.8*	1997-09	-3.4*							-3.4*	-3.4*
Black	1975-97	2.6*	1997-09	-2.9*									-2.9*	-2.9*
<u>U.S. Cancer Mortality<sup>c</sup>, 1992-2009</u>														
All Races	1992-94	3.4*	1994-98	0.2	1998-04	-3.8*	2004-09	-3.1*					-3.4*	-3.1*
White	1992-94	3.5*	1994-98	0.1	1998-04	-3.8*	2004-09	-3.0*					-3.4*	-3.0*
White NH <sup>ef</sup>	1992-94	4.0*	1994-98	-0.1	1998-09	-3.4*							-3.4*	-3.4*
Black	1992-97	2.3	1997-09	-2.7*									-2.7*	-2.7*
Black NH <sup>ef</sup>	1992-97	3.0	1997-09	-2.7*									-2.7*	-2.7*
API <sup>e</sup>	1992-09	-1.7*											-1.7*	-1.7*
AI/AN <sup>eg</sup>	1992-09	0.7											0.7	0.7
Hispanic <sup>f</sup>	1992-97	3.0	1997-09	-2.6*									-2.6*	-2.6*

Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from CT, DC, ME, MD, MN, NH, NY, ND, SC, OK and VT.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

\* The APC/AAPC is significantly different from zero ( $p < .05$ ).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.4  
Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidence<sup>a</sup> Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975	11.07	12.89	9.59	11.61	13.49	10.11	6.36	7.31	5.31
1976	11.21	12.83	10.03	11.65	13.29	10.50	5.95	7.45	4.87
1977	11.18	12.92	9.82	11.64	13.50	10.20	6.64	7.23	6.10
1978	11.93	14.29	10.12	12.48	14.77	10.74	7.15	9.46	5.17
1979	12.52	14.20	11.21	13.00	14.60	11.77	8.39	11.81	5.91
1980	12.61	15.01	10.80	12.96	15.26	11.21	8.77	10.89	7.20
1981	13.58	15.90	11.81	14.06	16.34	12.35	7.42	10.59	4.98
1982	13.39	15.56	11.61	14.02	16.41	12.05	10.27	10.22	10.01
1983	13.99	16.62	11.95	14.64	17.53	12.41	10.28	10.88	9.62
1984	15.19	18.31	12.77	15.96	19.12	13.51	9.47	12.52	6.92
1985	15.50	18.36	13.17	16.27	19.22	13.86	9.89	11.96	8.32
1986	15.92	19.43	13.03	16.83	20.55	13.77	10.67	13.13	8.53
1987	16.75	20.79	13.44	17.72	22.15	14.04	10.49	10.56	10.10
1988	17.25	21.33	14.08	18.21	22.41	14.91	11.58	15.81	8.48
1989	17.35	21.64	13.83	18.35	23.03	14.51	11.64	14.19	9.74
1990	18.52	23.00	14.81	19.37	23.98	15.54	13.83	17.54	10.93
1991	18.81	23.73	14.61	19.69	24.82	15.29	14.05	18.75	10.39
1992	18.63	23.05	14.96	19.59	23.98	15.86	13.64	18.77	9.65
1993	18.87	23.48	15.02	19.69	24.35	15.74	14.02	19.42	9.59
1994	19.97	25.01	15.79	20.70	25.62	16.58	14.45	21.69	8.67
1995	19.98	25.42	15.42	20.70	26.17	16.05	16.60	23.53	11.24
1996	19.41	24.24	15.46	20.30	25.27	16.22	15.23	18.93	12.10
1997	19.99	24.50	16.47	20.89	25.22	17.49	16.35	24.14	10.89
1998	19.63	22.98	16.85	20.64	24.06	17.79	14.24	16.62	12.33
1999	19.94	24.60	16.29	20.93	25.53	17.28	14.38	18.44	11.29
2000	19.74	24.23	16.11	20.92	25.59	17.11	13.86	18.36	10.52
2001	20.02	24.41	16.47	20.86	25.48	17.10	16.05	18.40	13.95
2002	20.22	24.21	17.08	21.34	25.52	17.99	14.54	17.36	12.45
2003	20.76	24.98	17.56	21.92	26.32	18.53	16.12	19.79	13.59
2004	21.38	25.94	17.89	22.36	26.93	18.83	18.57	24.25	14.47
2005	20.76	25.52	16.99	21.95	26.68	18.15	16.66	20.03	13.94
2006	20.39	24.53	17.20	21.62	25.84	18.33	16.35	20.79	13.06
2007	21.16	25.95	17.36	22.44	27.42	18.39	15.60	18.81	13.17
2008	20.80	25.43	17.05	21.68	26.53	17.72	16.61	18.37	14.94
2009	20.81	25.04	17.39	21.75	26.24	18.02	15.46	19.09	12.84

Additional information on the model used to delay-adjust SEER Incidence rates can be found at [\(http://surveillance.cancer.gov/delay/\)](http://surveillance.cancer.gov/delay/).

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval.

Table 19.5  
Non-Hodgkin Lymphoma

Age-adjusted SEER Incidence<sup>a</sup> Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975-2009	17.88	21.87	14.72	18.62	22.71	15.36	13.36	16.85	10.65
1975	11.07	12.89	9.59	11.61	13.49	10.11	6.36	7.31	5.31
1976	11.21	12.83	10.03	11.65	13.29	10.50	5.95	7.45	4.87
1977	11.18	12.92	9.82	11.64	13.50	10.20	6.64	7.23	6.10
1978	11.93	14.29	10.12	12.48	14.77	10.74	7.15	9.46	5.17
1979	12.52	14.20	11.21	13.00	14.60	11.77	8.39	11.81	5.91
1980	12.61	15.01	10.80	12.96	15.26	11.21	8.77	10.89	7.20
1981	13.58	15.90	11.81	14.06	16.34	12.35	7.42	10.59	4.98
1982	13.39	15.56	11.61	14.02	16.40	12.05	10.27	10.22	10.01
1983	13.99	16.62	11.95	14.64	17.52	12.41	10.28	10.88	9.62
1984	15.19	18.31	12.77	15.96	19.12	13.51	9.46	12.52	6.92
1985	15.49	18.36	13.17	16.27	19.22	13.85	9.89	11.96	8.32
1986	15.92	19.43	13.03	16.82	20.55	13.77	10.66	13.13	8.52
1987	16.75	20.79	13.43	17.71	22.14	14.03	10.48	10.55	10.09
1988	17.24	21.32	14.08	18.20	22.40	14.90	11.57	15.79	8.47
1989	17.34	21.63	13.83	18.34	23.01	14.49	11.62	14.17	9.72
1990	18.51	22.98	14.80	19.36	23.96	15.53	13.81	17.51	10.91
1991	18.80	23.72	14.60	19.67	24.80	15.28	14.03	18.72	10.37
1992	18.62	23.03	14.94	19.56	23.95	15.84	13.61	18.73	9.63
1993	18.85	23.46	15.00	19.66	24.31	15.72	13.98	19.37	9.56
1994	19.95	24.98	15.77	20.67	25.58	16.55	14.41	21.63	8.65
1995	19.95	25.38	15.39	20.66	26.12	16.02	16.55	23.45	11.19
1996	19.38	24.21	15.44	20.26	25.22	16.18	15.17	18.86	12.05
1997	19.95	24.45	16.43	20.84	25.16	17.44	16.27	24.04	10.84
1998	19.59	22.93	16.81	20.58	24.00	17.73	14.17	16.54	12.27
1999	19.88	24.53	16.24	20.84	25.43	17.21	14.28	18.32	11.20
2000	19.68	24.15	16.05	20.82	25.47	17.02	13.75	18.23	10.43
2001	19.94	24.32	16.39	20.74	25.34	17.00	15.90	18.24	13.81
2002	20.12	24.10	16.99	21.19	25.36	17.85	14.38	17.18	12.31
2003	20.63	24.84	17.45	21.74	26.11	18.37	15.92	19.55	13.41
2004	21.23	25.77	17.75	22.14	26.67	18.63	18.29	23.90	14.23
2005	20.58	25.30	16.83	21.68	26.38	17.91	16.36	19.69	13.67
2006	20.17	24.28	17.00	21.30	25.48	18.05	16.00	20.36	12.77
2007	20.88	25.63	17.12	22.04	26.95	18.04	15.20	18.35	12.82
2008	20.46	25.03	16.75	21.21	25.98	17.31	16.09	17.83	14.45
2009	20.21	24.35	16.86	20.95	25.32	17.33	14.70	18.19	12.19

<sup>a</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.6  
Non-Hodgkin Lymphoma

Age-adjusted U.S. Death<sup>a</sup> Rates by Year, Race and Sex

Year of Death:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975-2009	7.36	9.18	6.02	7.65	9.52	6.28	4.98	6.42	3.94
1975	5.63	6.92	4.65	5.83	7.15	4.82	3.74	4.83	2.92
1976	5.71	6.87	4.83	5.94	7.14	5.03	3.54	4.54	2.76
1977	5.77	6.88	4.92	5.96	7.10	5.10	3.89	4.89	3.12
1978	5.93	7.30	4.90	6.15	7.53	5.12	3.90	5.40	2.81
1979	5.95	7.40	4.88	6.18	7.70	5.08	3.65	4.50	2.98
1980	6.23	7.47	5.29	6.47	7.74	5.52	3.99	5.15	3.12
1981	6.16	7.38	5.27	6.40	7.66	5.47	3.98	5.00	3.25
1982	6.55	7.98	5.49	6.83	8.29	5.74	4.12	5.23	3.29
1983	6.66	8.11	5.58	6.92	8.39	5.85	4.30	5.79	3.23
1984	6.76	8.15	5.75	7.05	8.50	6.01	4.19	5.28	3.39
1985	7.06	8.80	5.80	7.34	9.17	6.02	4.62	5.57	3.87
1986	7.31	8.98	6.05	7.59	9.25	6.33	4.95	6.64	3.70
1987	7.26	8.81	6.10	7.56	9.12	6.38	4.73	6.30	3.62
1988	7.52	9.28	6.24	7.82	9.59	6.53	5.01	6.82	3.72
1989	7.83	9.73	6.43	8.12	10.04	6.71	5.33	7.10	4.07
1990	7.87	9.97	6.34	8.16	10.32	6.58	5.39	7.13	4.17
1991	8.19	10.15	6.74	8.50	10.52	7.00	5.70	7.17	4.61
1992	8.22	10.30	6.69	8.53	10.66	6.96	5.64	7.23	4.45
1993	8.25	10.14	6.86	8.57	10.45	7.17	5.69	7.53	4.40
1994	8.63	10.75	7.10	9.00	11.20	7.41	5.54	6.82	4.56
1995	8.72	10.81	7.16	9.09	11.21	7.49	5.79	7.62	4.45
1996	8.75	10.94	7.14	9.09	11.29	7.46	6.21	8.25	4.74
1997	8.88	11.03	7.25	9.21	11.35	7.57	6.34	8.45	4.87
1998	8.69	10.85	7.10	9.03	11.27	7.38	5.99	7.50	4.89
1999	8.32	10.36	6.85	8.67	10.71	7.18	5.65	7.44	4.41
2000	8.17	10.20	6.69	8.53	10.63	7.01	5.20	6.62	4.17
2001	7.90	9.97	6.40	8.20	10.30	6.67	5.62	7.31	4.47
2002	7.63	9.65	6.17	7.94	10.02	6.41	5.42	6.92	4.41
2003	7.36	9.38	5.89	7.66	9.79	6.09	4.95	5.88	4.27
2004	7.06	8.93	5.69	7.34	9.26	5.92	5.03	6.30	4.13
2005	6.91	8.85	5.51	7.20	9.20	5.74	4.79	6.19	3.80
2006	6.71	8.48	5.39	6.96	8.77	5.61	4.95	6.38	3.93
2007	6.55	8.36	5.21	6.81	8.66	5.43	4.56	5.88	3.62
2008	6.37	8.19	5.03	6.66	8.54	5.26	4.34	5.58	3.46
2009	6.26	8.13	4.87	6.51	8.42	5.07	4.54	6.28	3.42

<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.7  
Non-Hodgkin Lymphoma

SEER Incidence<sup>a</sup> and U.S. Death<sup>b</sup> Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence</u>									
<u>Age at Diagnosis</u>									
Age-Adjusted Rates, 2005-2009									
All ages	19.6	23.8	16.3	20.5	24.8	17.1	14.3	17.5	11.8
Under 65	9.4	11.2	7.6	9.6	11.4	7.8	9.2	11.5	7.1
65 and over	90.5	111.3	76.3	96.1	117.7	81.1	49.9	58.6	44.4
All ages (IARC world std) <sup>c</sup>	13.1	15.7	10.8	13.6	16.2	11.2	10.4	12.8	8.4
Age-Specific Rates, 2005-2009									
<1	-	-	-	-	-	-	-	-	-
1-4	0.6	0.8	0.4	0.6	0.7	0.4	0.8	-	-
5-9	0.9	1.2	0.6	0.9	1.3	0.5	0.7	0.9	-
10-14	1.3	1.8	0.7	1.3	1.8	0.7	1.4	1.8	0.9
15-19	1.8	2.2	1.4	1.8	2.2	1.4	2.0	2.4	1.6
20-24	2.4	3.0	1.9	2.4	2.9	1.9	2.5	3.3	1.7
25-29	3.3	3.8	2.9	3.3	3.8	2.8	3.7	4.5	2.9
30-34	4.9	5.6	4.1	4.6	5.2	3.9	7.1	9.4	5.0
35-39	7.1	8.5	5.6	7.0	8.5	5.4	8.8	11.3	6.4
40-44	10.4	12.7	8.0	10.6	13.1	7.9	11.0	13.0	9.1
45-49	15.0	18.1	12.0	15.4	18.5	12.3	14.9	19.5	10.9
50-54	21.8	25.7	18.0	22.4	26.3	18.6	21.7	26.5	17.6
55-59	31.3	36.9	26.0	32.3	37.5	27.4	28.4	37.5	20.8
60-64	45.7	53.6	38.5	47.9	55.7	40.6	34.4	41.8	28.6
65-69	64.5	76.7	53.8	68.1	80.3	57.2	43.6	52.1	37.2
70-74	82.4	96.4	71.0	88.0	102.5	75.9	47.8	53.8	43.6
75-79	102.9	126.9	85.2	110.3	135.2	91.5	52.0	62.3	45.5
80-84	118.7	145.0	102.1	125.8	153.4	108.2	59.4	68.5	54.5
85+	110.6	152.1	91.4	115.9	160.1	95.7	53.3	65.0	48.9
<u>U.S. Mortality</u>									
<u>Age at Death</u>									
Age-Adjusted Rates, 2005-2009									
All ages	6.6	8.4	5.2	6.8	8.7	5.4	4.6	6.1	3.6
Under 65	1.7	2.2	1.3	1.7	2.2	1.2	2.1	2.8	1.5
65 and over	39.8	50.9	32.4	42.0	53.6	34.2	22.1	28.5	18.4
All ages (IARC world std) <sup>c</sup>	3.6	4.6	2.8	3.7	4.8	2.9	3.0	3.9	2.3
Age-Specific Rates, 2005-2009									
<1	-	-	-	-	-	-	-	-	-
1-4	0.0	0.0	-	0.0	-	-	-	-	-
5-9	0.1	0.1	0.0	0.1	0.1	-	-	-	-
10-14	0.1	0.2	0.1	0.1	0.2	0.1	0.1	-	-
15-19	0.2	0.3	0.1	0.2	0.3	0.1	0.3	0.4	-
20-24	0.4	0.5	0.2	0.3	0.5	0.2	0.5	0.6	0.5
25-29	0.5	0.6	0.3	0.4	0.5	0.3	0.7	0.9	0.5
30-34	0.6	0.8	0.5	0.6	0.7	0.4	1.0	1.3	0.8
35-39	0.9	1.1	0.7	0.8	1.0	0.6	1.4	1.7	1.1
40-44	1.5	1.9	1.0	1.4	1.8	0.9	2.3	3.0	1.7
45-49	2.3	3.0	1.7	2.3	2.9	1.6	3.2	4.2	2.4
50-54	4.0	5.3	2.7	4.0	5.2	2.8	4.9	7.0	3.1
55-59	6.9	9.0	5.0	7.0	8.9	5.0	7.9	11.1	5.3
60-64	11.5	14.5	8.8	11.8	14.9	9.0	10.9	14.2	8.3
65-69	18.4	23.5	13.9	19.2	24.4	14.6	14.5	19.1	11.2
70-74	28.8	36.3	22.7	30.5	38.2	24.1	18.5	24.6	14.3
75-79	44.6	55.6	36.4	47.4	59.0	38.6	22.8	27.5	20.0
80-84	61.7	78.2	51.3	65.3	82.4	54.2	30.1	36.4	26.8
85+	76.1	101.9	64.5	80.1	106.8	67.9	35.5	49.8	30.3

<sup>a</sup> SEER 18 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

<sup>b</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

<sup>c</sup> Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

- Rates are per 100,000 and are age-adjusted to the IARC world standard population.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.8  
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 <sup>a</sup>	-	-	-	31	31	31	-	-	-
1970-1973 <sup>a</sup>	-	-	-	41	39	43	-	-	-
1975-1977 <sup>b</sup>	46.7	45.6	47.8	47.0	46.4	47.6	48.4	42.6	54.9 <sup>g</sup>
1978-1980 <sup>b</sup>	48.1	46.2	50.1	48.1	46.4	49.9	51.1	47.1	56.7
1981-1983 <sup>b</sup>	50.9	50.5	51.2	51.1	50.7	51.4	49.9	49.4	50.4
1984-1986 <sup>b</sup>	51.8	50.2	53.5	52.1	50.8	53.7	47.1	44.5	50.4
1987-1989 <sup>b</sup>	51.1	47.9	55.1	51.6	48.4	55.4	46.4	41.7	52.1
1990-1992 <sup>b</sup>	50.9	46.8	56.0	51.7	47.7	56.7	42.1	38.2	47.6
1993-1995 <sup>b</sup>	52.7	49.0	57.6	53.5	50.0	57.9	42.0	36.0	53.5
1996-1998 <sup>b</sup>	59.0	57.2	61.2	59.7	57.8	61.8	54.0	52.5	56.3
1999-2001 <sup>b</sup>	64.1	61.6	67.1	65.1	63.0	67.6	55.8	49.0	63.8
2002-2008 <sup>b</sup>	70.6 <sup>f</sup>	69.5 <sup>f</sup>	71.9 <sup>f</sup>	71.8 <sup>f</sup>	71.0 <sup>f</sup>	72.7 <sup>f</sup>	62.8 <sup>f</sup>	58.7 <sup>f</sup>	67.4 <sup>f</sup>
5-Year Period Survival (Percent) <sup>cd</sup>									
2008	69.0	67.6	70.6	69.6	68.5	70.9	60.8	56.5	65.8
Stage Distribution (%) 2002-2008 <sup>ee</sup>									
All Stages									
Number of cases	89,792	48,135	41,657	75,733	40,620	35,113	7,103	3,834	3,269
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	28	27	30	28	27	29	27	25	30
Regional	15	15	16	15	15	16	15	14	16
Distant	48	50	46	49	51	46	50	54	47
Unstaged	8	8	9	8	8	9	8	7	8
5-Year Relative Survival (Percent), 2002-2008 <sup>c</sup>									
Age at Diagnosis:									
Ages <45	77.5	74.5	82.4	79.5	76.3	85.1	63.9	61.1	68.0
Ages 45-54	77.3	74.0	82.2	79.0	75.8	83.7	63.6	57.4	72.4
Ages 55-64	74.0	70.6	78.4	74.9	71.8	79.0	63.8	58.0	71.1
Ages 65-74	68.6	65.3	72.1	69.3	66.2	72.6	59.9	50.9	67.8
Ages 75+	52.3	51.5	53.0	53.0	52.4	53.5	47.1	45.3	47.8
Ages <65	76.1	72.9	80.6	77.4	74.4	81.9	63.9	59.2	70.4
Ages 65+	59.7	58.3	60.9	60.2	59.0	61.3	54.5	49.2	58.2
Stage <sup>e</sup> :									
All Stages	68.2	66.6	70.0	68.8	67.5	70.2	61.3	57.0	66.2
Localized	81.2	80.3	82.1	81.5	80.9	82.1	76.7	72.6	80.9
Regional	71.9	71.2	72.6	72.5	72.1	72.8	66.9	63.5	70.3
Distant	59.9	58.5	61.8	61.0	59.8	62.6	51.1	47.9	55.3
Unstaged	65.0	63.5	66.6	63.8	62.4	65.3	60.5	55.3	65.0

<sup>a</sup> Based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Based on follow-up of patients into 2009.

<sup>c</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).  
Based on follow-up of patients into 2009.

<sup>d</sup> Period survival provides a 2008 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2006-2008: 0-1 year survival), (2005-2007: 1-2 year survival), (2004-2006: 2-3 year survival), (2003-2005: 3-4 year survival), (2002-2004: 4-5 years survival).

<sup>e</sup> Stage at diagnosis is classified using SEER Summary Stage 2000.

<sup>f</sup> The difference between 1975-1977 and 2002-2008 is statistically significant (p<.05).

<sup>g</sup> The standard error is between 5 and 10 percentage points.

<sup>h</sup> The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.



Table 19.9  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																					
	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
1-year	71.1	73.8	72.0	70.7	70.3	71.4	71.8	71.2	70.7	73.7	76.4	77.2	77.9	77.5	79.2	81.4	80.6	81.4	81.7	81.3	81.7	84.4
2-year	60.6	64.2	63.1	61.4	61.3	62.5	63.7	63.3	62.2	66.0	68.6	70.2	71.3	71.5	73.5	76.1	75.8	76.0	77.1	76.9	77.3	
3-year	54.9	58.7	58.4	56.7	56.8	58.1	58.9	58.8	57.6	62.2	65.0	66.4	67.0	67.8	70.3	73.2	73.2	73.6	74.5	74.4		
4-year	50.8	54.7	54.5	52.5	54.0	54.7	55.9	55.4	54.8	58.8	62.1	63.8	64.6	65.5	68.2	71.2	71.8	71.4	72.5			
5-year	47.0	51.0	51.2	49.9	51.2	51.5	53.1	53.0	52.1	56.1	59.6	61.2	62.3	63.7	66.2	69.4	70.1	70.0				
6-year	43.7	47.7	48.5	47.4	48.4	49.0	50.9	51.0	49.9	54.2	57.3	58.4	59.5	62.1	64.8	68.1	68.4					
7-year	41.0	45.2	46.0	44.5	45.5	46.6	49.2	49.1	48.1	52.3	55.2	56.5	57.7	60.3	63.1	66.2						
8-year	38.6	43.0	43.6	42.4	43.1	45.0	47.2	47.3	46.3	50.4	53.0	55.3	56.2	58.7	61.5							
9-year	36.6	40.9	41.6	40.9	41.5	43.9	45.7	45.6	45.1	49.3	51.7	53.5	54.6	57.3								
10-year	35.2	39.0	39.9	39.8	40.3	42.3	44.3	43.9	44.4	48.1	50.4	52.3	53.4									
11-year	33.6	37.5	38.5	38.0	38.9	41.0	42.9	42.4	43.3	46.5	48.8	51.1										
12-year	32.5	36.0	37.0	36.5	38.0	40.0	41.8	41.4	42.1	45.6	48.2											
13-year	31.5	34.8	35.7	35.3	37.4	38.9	40.2	39.9	41.3	44.6												
14-year	30.3	33.6	34.7	34.3	36.2	37.6	39.0	38.6	40.4													
15-year	29.0	32.3	33.6	33.9	34.9	36.9	38.6	37.8														
16-year	28.0	31.2	32.8	32.7	34.1	36.2	37.4															
17-year	27.4	30.4	32.0	32.3	33.1	35.6																
18-year	26.8	29.6	31.3	31.8	32.2																	
19-year	26.1	28.8	30.5	31.1																		
20-year	25.3	28.0	30.0																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.10  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Survival Time																						
1-year	70.3	73.5	69.7	66.6	66.8	68.4	68.7	68.0	67.2	71.7	75.6	75.4	76.6	76.6	78.2	81.1	80.1	80.5	81.1	81.4	81.5	83.8
2-year	59.8	64.2	60.7	57.6	57.2	58.2	59.7	60.0	58.8	63.7	67.3	68.4	69.6	70.4	71.5	75.4	74.9	75.5	76.0	76.4	77.7	
3-year	53.7	58.4	55.9	52.4	52.6	54.3	54.9	55.1	54.5	60.0	63.9	64.7	64.4	66.6	68.3	72.3	72.7	72.8	72.8	73.4		
4-year	49.6	54.1	51.7	48.5	49.9	50.6	51.8	51.7	51.7	56.4	61.0	62.2	61.7	63.7	65.8	70.2	71.0	70.1	70.8			
5-year	45.6	50.4	48.4	46.1	47.7	46.6	48.9	49.1	48.8	53.7	58.4	59.4	59.3	61.6	63.8	68.1	69.0	68.8				
6-year	42.6	46.9	45.6	44.2	45.0	44.8	46.9	47.5	46.8	51.2	56.2	56.6	56.3	60.2	62.1	66.8	67.0					
7-year	40.0	44.3	43.3	41.4	42.2	42.6	46.1	45.9	45.1	49.2	54.3	54.7	54.6	58.4	60.2	65.4						
8-year	37.9	42.2	41.1	39.7	39.8	41.2	44.3	43.9	43.2	47.4	52.0	53.5	53.6	56.5	58.5							
9-year	35.7	40.2	39.2	38.2	38.2	40.2	43.0	42.0	42.2	46.4	50.5	51.5	52.2	54.9								
10-year	34.2	38.1	37.7	37.3	37.2	38.6	42.2	40.6	41.7	45.5	49.1	50.6	51.4									
11-year	32.9	36.4	36.4	36.0	36.2	38.1	40.6	39.5	40.8	43.8	47.6	49.6										
12-year	32.0	35.2	35.1	34.5	35.5	37.4	40.0	38.7	39.4	42.7	47.2											
13-year	30.8	34.2	34.2	33.3	34.9	36.2	38.6	37.4	38.8	41.9												
14-year	29.5	33.1	33.2	32.4	33.9	34.4	37.3	36.5	37.6													
15-year	28.1	32.0	32.3	32.2	32.4	33.7	37.1	35.8														
16-year	27.1	30.8	31.6	30.6	31.7	33.1	35.8															
17-year	26.5	30.0	30.8	30.3	31.0	32.2																
18-year	26.1	29.3	30.2	29.9	30.4																	
19-year	25.6	28.8	29.3	29.1																		
20-year	25.1	27.9	29.1																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.11  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Survival Time																						
1-year	71.9	74.2	74.7	75.8	74.9	75.1	75.8	75.4	75.3	76.3	77.3	79.2	79.5	78.5	80.4	81.7	81.3	82.4	82.4	81.1	82.0	85.1
2-year	61.5	64.2	65.9	66.2	66.7	67.9	68.8	67.7	66.6	68.9	70.1	72.1	73.3	72.8	75.8	76.9	76.7	76.6	78.5	77.4	76.8	
3-year	56.1	59.1	61.4	61.9	62.3	62.9	64.0	63.6	61.6	65.1	66.3	68.3	70.2	69.2	72.7	74.2	73.9	74.6	76.5	75.5		
4-year	52.1	55.4	57.9	57.5	59.5	59.9	61.1	60.2	58.9	61.9	63.5	65.6	68.2	67.5	71.1	72.4	72.6	72.8	74.4			
5-year	48.5	51.7	54.6	54.6	55.8	57.5	58.4	57.9	56.6	59.1	61.1	63.1	65.8	66.4	69.1	70.9	71.4	71.4				
6-year	44.9	48.6	51.8	51.3	53.0	54.2	56.0	55.5	53.9	58.0	58.5	60.4	63.4	64.5	68.0	69.5	69.8					
7-year	42.0	46.1	49.3	48.4	49.7	51.6	53.1	53.1	52.0	56.2	56.4	58.6	61.3	62.5	66.5	67.1						
8-year	39.4	43.8	46.5	45.8	47.4	49.7	50.9	51.7	50.3	54.1	54.2	57.2	59.4	61.3	65.0							
9-year	37.6	41.7	44.4	44.3	45.8	48.5	49.1	50.3	49.0	52.9	53.1	55.8	57.6	60.3								
10-year	36.3	40.0	42.4	42.9	44.2	47.0	47.0	48.1	47.9	51.2	52.0	54.2	55.8									
11-year	34.4	38.6	41.0	40.5	42.4	44.6	45.8	46.0	46.7	49.9	50.2	52.8										
12-year	33.0	36.9	39.2	39.1	41.2	43.2	44.1	44.9	45.8	49.1	49.4											
13-year	32.3	35.4	37.6	37.8	40.5	42.2	42.3	43.2	44.8	47.9												
14-year	31.1	34.2	36.5	36.6	39.0	41.6	41.0	41.1	43.8													
15-year	30.0	32.6	35.2	35.8	38.0	40.9	40.5	40.4														
16-year	28.9	31.7	34.2	35.3	37.3	39.9	39.3															
17-year	28.3	30.8	33.6	34.8	35.8	39.6																
18-year	27.5	29.8	32.6	34.1	34.6																	
19-year	26.6	28.7	31.9	33.6																		
20-year	25.5	27.9	31.0																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.12

## Non-Hodgkin Lymphoma

## Number of Cases

By SEER Location and Year of Diagnosis, 1975-2009

All Races, Males, All Ages

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009
SEER 9 <sup>b</sup>	5,223	2,506	2,704	3,174	3,627	3,989	4,569	4,728	5,324	5,245	5,254	5,532	5,751	6,197	6,312	6,530
SEER 9 except SF-Oakland	4,284	2,088	2,267	2,599	2,818	3,087	3,506	3,695	4,157	4,236	4,355	4,487	4,804	5,183	5,322	5,481
San Francisco- Oakland SMSA <sup>c</sup>	939	418	437	575	809	902	1,063	1,033	1,167	1,009	899	1,045	947	1,014	990	1,049
San Francisco City/County	245	96	123	210	326	393	467	410	451	353	213	256	218	283	217	212

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2009

All Races, Males, All Ages

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009
SEER 9 <sup>b</sup>	13.4	15.5	16.1	18.3	20.1	21.5	23.4	23.2	25.2	24.3	23.7	24.2	24.5	25.5	25.0	24.7
SEER 9 except SF-Oakland	13.2	15.4	16.1	18.1	18.8	20.0	21.7	21.8	23.6	23.5	23.5	23.4	24.3	25.4	24.9	24.6
San Francisco- Oakland SMSA <sup>c</sup>	14.8	15.8	16.0	19.5	26.8	28.4	31.7	30.4	33.5	28.7	25.2	28.5	25.2	26.4	25.1	25.4
San Francisco City/County	14.3	14.4	17.6	29.3	44.4	51.9	61.0	52.3	57.5	44.6	27.4	32.4	26.3	34.7	25.5	24.5

<sup>a</sup> Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.13

## Non-Hodgkin Lymphoma

## Number of Cases

By SEER Location and Year of Diagnosis, 1975-2009

All Races, Males, Ages 0-19

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009
SEER 9 <sup>b</sup>	223	88	108	89	94	85	100	89	119	105	105	119	127	108	106	143
SEER 9 except SF-Oakland	191	79	95	80	80	77	86	74	106	84	93	100	115	92	87	114
San Francisco- Oakland SMSA <sup>c</sup>	32	9	13	9	14	8	14	15	13	21	12	19	12	16	19	29
San Francisco City/County	9	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	5

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2009

All Races, Males, Ages 0-19

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009
SEER 9 <sup>b</sup>	1.2	1.3	1.6	1.3	1.4	1.3	1.5	1.3	1.6	1.4	1.4	1.5	1.6	1.4	1.3	1.8
SEER 9 except SF-Oakland	1.2	1.3	1.6	1.4	1.4	1.3	1.5	1.2	1.7	1.3	1.4	1.5	1.7	1.4	1.3	1.6
San Francisco- Oakland SMSA <sup>c</sup>	1.4	1.0	1.5	1.0	1.6	0.9	1.5	1.6	1.3	2.1	1.2	1.8	1.2	1.6	1.9	2.8
San Francisco City/County	2.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.7

<sup>a</sup> Rates are per 100,000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.14

## Non-Hodgkin Lymphoma

## Number of Cases

By SEER Location and Year of Diagnosis, 1975-2009

All Races, Males, Ages 20-54

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009
SEER 9 <sup>b</sup>	1,465	686	723	956	1,210	1,408	1,764	1,831	2,090	1,757	1,606	1,681	1,610	1,713	1,634	1,650
SEER 9 except SF-Oakland	1,208	562	588	728	826	919	1,193	1,295	1,484	1,314	1,267	1,313	1,300	1,400	1,364	1,366
San Francisco- Oakland SMSA <sup>c</sup>	257	124	135	228	384	489	571	536	606	443	339	368	310	313	270	284
San Francisco City/County	58	29	34	105	215	288	333	303	317	224	105	115	110	111	85	74

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2009

All Races, Males, Ages 20-54

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009
SEER 9 <sup>b</sup>	6.9	7.9	8.2	10.4	12.4	13.5	15.9	15.6	16.9	13.7	12.1	12.2	11.5	12.1	11.3	11.3
SEER 9 except SF-Oakland	6.9	7.8	8.1	9.7	10.3	10.8	13.1	13.4	14.4	12.2	11.5	11.4	11.1	11.7	11.2	11.1
San Francisco- Oakland SMSA <sup>c</sup>	7.0	8.4	8.9	13.9	22.6	26.4	29.5	26.7	29.8	21.2	15.6	16.3	13.6	14.0	12.0	12.3
San Francisco City/County	6.7	8.8	9.4	27.2	56.5	71.5	81.3	72.4	74.4	50.7	23.0	25.1	23.4	24.4	18.7	15.7

<sup>a</sup> Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.15

## Non-Hodgkin Lymphoma

## Number of Cases

By SEER Location and Year of Diagnosis, 1975-2009

All Races, Males, Ages 55+

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009
SEER 9 <sup>b</sup>	3,535	1,732	1,873	2,129	2,323	2,496	2,705	2,808	3,115	3,383	3,543	3,732	4,014	4,376	4,572	4,737
SEER 9 except SF-Oakland	2,885	1,447	1,584	1,791	1,912	2,091	2,227	2,326	2,567	2,838	2,995	3,074	3,389	3,691	3,871	4,001
San Francisco- Oakland SMSA <sup>c</sup>	650	285	289	338	411	405	478	482	548	545	548	658	625	685	701	736
San Francisco City/County	178	65	88	104	109	105	132	106	131	126	106	141	107	169	130	133

Age-Adjusted Cancer Incidence Rates<sup>a</sup>

By SEER Location and Year of Diagnosis, 1975-2009

All Races, Males, Ages 55+

## Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009
SEER 9 <sup>b</sup>	45.1	52.2	54.0	59.7	63.3	67.3	70.1	70.6	76.1	80.0	81.0	82.8	85.4	89.3	88.6	86.6
SEER 9 except SF-Oakland	44.0	52.1	54.4	60.1	62.0	66.7	68.8	69.2	74.3	79.6	81.2	80.9	85.6	89.5	88.9	86.7
San Francisco- Oakland SMSA <sup>c</sup>	50.9	52.8	52.0	57.5	70.3	70.3	77.3	78.0	85.5	82.1	79.8	92.8	84.6	88.6	86.9	86.2
San Francisco City/County	48.2	44.6	59.8	72.7	73.9	75.7	93.4	74.7	92.1	87.2	72.7	92.9	67.5	102.1	73.3	72.6

<sup>a</sup> Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).<sup>b</sup> The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.<sup>c</sup> The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.16  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Both Sexes, 2007-2009 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.02	0.05	2.12	0.79	Asian/ Pacific Islander	0	0.01	0.02	0.04	1.84	0.73
	10	0.02	0.05	0.10	2.14	0.80		10	0.01	0.03	0.08	1.84	0.74
	20	0.03	0.09	0.21	2.13	0.80		20	0.02	0.06	0.14	1.84	0.73
	30	0.06	0.18	0.43	2.12	0.80		30	0.04	0.12	0.28	1.82	0.73
	40	0.13	0.38	0.85	2.09	0.80		40	0.08	0.24	0.58	1.79	0.73
	50	0.26	0.74	1.40	2.02	0.81		50	0.16	0.50	1.03	1.74	0.73
	60	0.51	1.21	1.75	1.87	0.80		60	0.35	0.89	1.41	1.63	0.72
	70	0.80	1.41	-	1.55	0.76		70	0.59	1.14	-	1.38	0.67
80	0.84	-	-	1.04	0.63	80	0.68	-	-	0.96	0.55		
White	0	0.01	0.02	0.05	2.23	0.83	American Indian/ Alaska Native <sup>a</sup>	0	0.01	0.02	0.04	1.26	0.49
	10	0.02	0.04	0.10	2.25	0.84		10	0.01	0.03	0.06	1.27	0.50
	20	0.03	0.09	0.21	2.24	0.84		20	0.02	0.04	0.10	1.26	0.50
	30	0.06	0.19	0.44	2.23	0.85		30	0.03	0.09	0.22	1.27	0.51
	40	0.13	0.39	0.88	2.20	0.85		40	0.06	0.20	0.52	1.28	0.53
	50	0.27	0.78	1.48	2.12	0.85		50	0.14	0.48	0.84	1.27	0.54
	60	0.54	1.28	1.84	1.97	0.85		60	0.37	0.75	1.11	1.22	0.54
	70	0.85	1.49	-	1.63	0.81		70	0.45	0.86	-	0.99	0.51
80	0.88	-	-	1.08	0.66	80	0.58	-	-	0.75	0.37		
Black	0	0.01	0.02	0.06	1.22	0.43	Hispanic <sup>b</sup>	0	0.01	0.02	0.04	2.13	0.75
	10	0.02	0.05	0.12	1.24	0.44		10	0.01	0.04	0.09	2.14	0.76
	20	0.03	0.11	0.23	1.23	0.44		20	0.03	0.08	0.19	2.14	0.76
	30	0.07	0.20	0.41	1.21	0.44		30	0.05	0.16	0.38	2.13	0.76
	40	0.13	0.34	0.64	1.16	0.44		40	0.11	0.33	0.78	2.10	0.76
	50	0.22	0.54	0.85	1.08	0.43		50	0.23	0.69	1.30	2.03	0.75
	60	0.35	0.69	0.90	0.95	0.41		60	0.48	1.13	1.68	1.89	0.74
	70	0.41	0.68	-	0.74	0.36		70	0.71	1.32	-	1.56	0.69
80	0.39	-	-	0.49	0.28	80	0.78	-	-	1.08	0.55		

Devcan Version 6.6.1, April 2012, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire, North Dakota and South Carolina.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.



Table 19.17  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Males, 2007-2009 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.03	0.06	2.34	0.88	Asian/ Pacific Islander	0	0.01	0.03	0.05	2.06	0.82
	10	0.02	0.05	0.12	2.36	0.89		10	0.01	0.04	0.08	2.07	0.83
	20	0.03	0.10	0.25	2.35	0.89		20	0.02	0.06	0.15	2.06	0.83
	30	0.07	0.22	0.51	2.35	0.90		30	0.04	0.13	0.32	2.05	0.83
	40	0.15	0.44	0.98	2.32	0.91		40	0.09	0.28	0.69	2.03	0.83
	50	0.30	0.86	1.59	2.24	0.91		50	0.19	0.61	1.24	1.97	0.83
	60	0.60	1.39	1.97	2.10	0.91		60	0.44	1.09	1.68	1.86	0.82
	70	0.94	1.61	-	1.77	0.88		70	0.72	1.37	-	1.57	0.77
80	0.99	-	-	1.22	0.74	80	0.83	-	-	1.08	0.63		
White	0	0.01	0.03	0.06	2.46	0.93	American Indian/ Alaska Native <sup>a</sup>	0	0.01	0.03	0.05	1.32	0.43
	10	0.02	0.05	0.12	2.48	0.94		10	0.02	0.04	0.07	1.33	0.43
	20	0.03	0.10	0.25	2.47	0.94		20	0.02	0.05	0.13	1.32	0.44
	30	0.07	0.22	0.52	2.47	0.95		30	0.03	0.11	0.26	1.33	0.45
	40	0.15	0.45	1.02	2.43	0.95		40	0.08	0.24	0.64	1.35	0.46
	50	0.31	0.89	1.68	2.36	0.96		50	0.17	0.59	0.99	1.34	0.48
	60	0.63	1.47	2.07	2.21	0.96		60	0.46	0.90	1.28	1.29	0.47
	70	1.00	1.70	-	1.86	0.92		70	0.52	0.98	-	0.99	0.42
80	1.04	-	-	1.27	0.77	80	0.66	-	-	0.69	0.22		
Black	0	0.01	0.03	0.07	1.30	0.48	Hispanic <sup>b</sup>	0	0.01	0.02	0.05	2.20	0.83
	10	0.02	0.06	0.16	1.33	0.49		10	0.02	0.05	0.10	2.22	0.84
	20	0.04	0.14	0.29	1.32	0.49		20	0.03	0.09	0.21	2.22	0.84
	30	0.10	0.25	0.51	1.30	0.49		30	0.06	0.18	0.43	2.21	0.84
	40	0.16	0.43	0.75	1.24	0.49		40	0.12	0.38	0.85	2.18	0.84
	50	0.28	0.63	0.93	1.14	0.48		50	0.26	0.75	1.40	2.12	0.84
	60	0.40	0.74	0.94	0.98	0.46		60	0.52	1.21	1.75	1.97	0.84
	70	0.45	0.71	-	0.77	0.41		70	0.78	1.40	-	1.65	0.78
80	0.44	-	-	0.54	0.33	80	0.83	-	-	1.17	0.65		

Devcan Version 6.6.1, April 2012, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire, North Dakota and South Carolina.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.18  
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,  
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and  
Lifetime Risk of Dying from Cancer Given Alive at Current Age  
Females, 2007-2009 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.02	0.04	1.93	0.71	Asian/ Pacific Islander	0	0.00	0.01	0.04	1.65	0.66
	10	0.01	0.03	0.08	1.94	0.72		10	0.01	0.03	0.07	1.66	0.66
	20	0.02	0.07	0.17	1.94	0.72		20	0.02	0.07	0.14	1.65	0.66
	30	0.05	0.15	0.36	1.92	0.72		30	0.04	0.11	0.25	1.63	0.66
	40	0.10	0.31	0.72	1.89	0.72		40	0.07	0.21	0.48	1.60	0.66
	50	0.21	0.63	1.22	1.83	0.72		50	0.14	0.41	0.85	1.54	0.65
	60	0.44	1.05	1.56	1.69	0.72		60	0.28	0.73	1.19	1.44	0.64
	70	0.68	1.25	-	1.40	0.68		70	0.48	0.97	-	1.23	0.60
80	0.74	-	-	0.93	0.56	80	0.58	-	-	0.89	0.49		
White	0	0.00	0.01	0.04	2.03	0.75	American Indian/ Alaska Native <sup>a</sup>	0	0.00	0.01	0.02	1.18	0.54
	10	0.01	0.03	0.08	2.04	0.76		10	0.01	0.02	0.04	1.19	0.55
	20	0.02	0.07	0.17	2.03	0.76		20	0.01	0.03	0.08	1.19	0.56
	30	0.05	0.15	0.37	2.02	0.76		30	0.02	0.07	0.18	1.19	0.56
	40	0.10	0.32	0.75	1.99	0.76		40	0.05	0.16	0.42	1.19	0.57
	50	0.22	0.66	1.29	1.92	0.76		50	0.12	0.39	0.71	1.19	0.58
	60	0.46	1.12	1.65	1.78	0.76		60	0.29	0.63	0.97	1.14	0.59
	70	0.73	1.32	-	1.47	0.72		70	0.39	0.78	-	0.97	0.57
80	0.78	-	-	0.97	0.59	80	0.51	-	-	0.77	0.45		
Black	0	0.01	0.02	0.04	1.14	0.39	Hispanic <sup>b</sup>	0	0.01	0.02	0.04	2.07	0.69
	10	0.01	0.04	0.09	1.16	0.39		10	0.01	0.03	0.08	2.09	0.70
	20	0.02	0.08	0.17	1.15	0.39		20	0.02	0.07	0.16	2.08	0.70
	30	0.05	0.15	0.32	1.14	0.39		30	0.05	0.14	0.34	2.07	0.69
	40	0.10	0.27	0.55	1.10	0.39		40	0.10	0.29	0.72	2.04	0.69
	50	0.18	0.47	0.78	1.04	0.38		50	0.20	0.63	1.22	1.97	0.69
	60	0.32	0.65	0.88	0.93	0.37		60	0.45	1.05	1.62	1.83	0.67
	70	0.39	0.66	-	0.72	0.33		70	0.66	1.27	-	1.50	0.62
80	0.37	-	-	0.46	0.25	80	0.75	-	-	1.03	0.50		

Devcan Version 6.6.1, April 2012, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

<sup>a</sup> Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Underlying mortality data for Hispanics exclude deaths from the District of Columbia, Minnesota, New Hampshire, North Dakota and South Carolina.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.19  
Non-Hodgkin Lymphoma

SEER Incidence and U.S. Mortality  
Age-Adjusted Rates and Trends<sup>a</sup>  
By Race/Ethnicity and Sex

SEER Incidence	SEER 18 Areas <sup>b</sup>			SEER 13 Areas <sup>b</sup>			SEER 9 Areas <sup>b</sup>		
	Rate 2005-2009			Trend 2000-2009 <sup>c</sup>			Trend 2000-2009 <sup>d</sup>		
	Rate per 100,000 persons			AAPC (%)			AAPC (%)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
RACE/ETHNICITY									
All Races	19.6	23.8	16.3	0.4*	0.1	0.1	0.5*	0.3*	0.1
White	20.5	24.8	17.1	0.4*	0.1	0.1	0.0	0.4*	-0.1
White Hispanic <sup>e</sup>	17.7	19.9	15.8	0.2	-0.3	0.9*	-	-	-
White Non-Hispanic <sup>e</sup>	21.0	25.6	17.3	0.5*	0.3*	0.0	-	-	-
Black	14.3	17.5	11.8	0.5	-0.3	0.4	0.3	-0.7	2.4*
Asian/Pacific Islander	13.2	16.3	10.9	0.2	0.1	0.5	-	-	-
Amer Ind/Alaska Nat <sup>f</sup>	12.5	14.6	10.7	2.8*	-	-	-	-	-
Hispanic <sup>e</sup>	17.3	19.5	15.4	0.3*	-0.2	1.0*	-	-	-
U.S. Mortality <sup>g</sup>									
	Rate 2005-2009			Trend 2000-2009 <sup>h</sup>					
	Rate per 100,000 persons			AAPC (%)					
	Total	Males	Females	Total	Males	Females			
RACE/ETHNICITY									
All Races	6.6	8.4	5.2	-3.0*	-2.7*	-3.4*			
White	6.8	8.7	5.4	-3.0*	-2.7*	-3.4*			
White Hispanic <sup>e</sup>	5.4	6.6	4.5	-2.6*	-2.1*	-2.6*			
White Non-Hispanic <sup>e</sup>	6.9	8.9	5.5	-2.9*	-2.6*	-3.4*			
Black	4.6	6.1	3.6	-2.8*	-1.8*	-2.7*			
Asian/Pacific Islander	4.2	5.2	3.4	-2.1*	-2.3*	-1.7*			
Amer Ind/Alaska Nat									
Total U.S.	3.7	4.1	3.3	-1.4	-3.7*	-1.1			
CHSDA Counties	4.7	5.0	4.5	0.0	-1.1	0.7			
Non-CHSDA Counties	2.4	3.0	1.9	-12.5	-	-			
Hispanic <sup>e</sup>	5.2	6.3	4.3	-2.7*	-3.0*	-2.6*			

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends

are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry, and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG.

c The 2000-2009 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints over diagnosis years 1992-2009.

d The 2000-2009 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints over diagnosis years 1975-2009.

e Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2005-2009 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, North Dakota, and South Carolina. The 2000-2009 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, South Carolina and Vermont.

f Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

g US Mortality Files, National Center for Health Statistics, CDC.

h The 2000-2009 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2009.

\* The APC is significantly different from zero (p<.05).

Table 19.20  
Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Rates<sup>a</sup>  
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence Rates<sup>a</sup>, 2005-2009</u>									
California	18.91	22.97	15.60	19.74	23.93	16.27	14.06	17.04	11.68
Greater Bay Area	20.35	25.07	16.39	22.31	27.49	17.77	16.07	17.85	14.69
San Francisco-Oakland	20.18	25.40	15.94	22.32	28.26	17.24	16.11	17.57	15.04
San Jose-Monterey	20.79	24.55	17.39	22.36	26.18	18.78	16.75	20.07	13.18
Los Angeles	18.39	22.27	15.28	19.77	23.79	16.50	13.96	17.63	11.22
Greater California	18.64	22.53	15.48	18.98	22.93	15.76	13.28	16.49	10.62
Connecticut	21.38	25.95	17.95	21.53	26.04	18.15	16.03	18.42	13.90
Detroit	20.90	24.71	18.05	22.20	26.25	19.13	15.77	18.67	13.63
Georgia	17.43	21.57	14.18	18.51	22.48	15.30	13.62	17.65	10.67
Atlanta	17.76	22.44	14.31	18.93	23.47	15.46	15.31	20.20	12.04
Rural Georgia	16.71	23.44	11.12	19.63	24.16	15.26	10.59	20.48	-
Greater Georgia	17.18	20.98	14.10	18.25	21.95	15.20	12.50	15.81	9.87
Hawaii	16.53	20.91	12.97	20.00	26.79	13.52	-	-	-
Iowa	22.07	26.53	18.49	21.94	26.38	18.40	19.18	25.41	13.02
Kentucky	20.64	25.12	17.25	20.86	25.35	17.44	14.79	18.35	12.10
Louisiana	20.04	24.22	16.77	22.07	26.51	18.51	13.84	16.43	11.83
New Jersey	21.07	25.53	17.64	22.01	26.55	18.51	14.57	17.64	12.17
New Mexico	16.61	19.10	14.46	16.97	19.62	14.68	12.86	-	-
Seattle-Puget Sound	23.33	28.41	19.14	23.90	28.94	19.71	16.23	18.17	13.76
Utah	18.95	22.98	15.47	19.25	23.32	15.74	-	-	-
9 SEER Areas <sup>b</sup>	20.45	24.91	16.90	21.43	26.01	17.71	15.65	18.87	13.16
11 SEER Areas <sup>b</sup>	20.01	24.31	16.56	21.13	25.56	17.51	15.27	18.56	12.72
13 SEER Areas <sup>b</sup>	19.98	24.28	16.53	21.12	25.56	17.50	15.21	18.59	12.60
18 SEER Areas <sup>b</sup>	19.65	23.84	16.31	20.54	24.83	17.09	14.30	17.49	11.81

<sup>a</sup> Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

<sup>b</sup> The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles.

The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.21  
Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Rates<sup>a</sup>  
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Death Rates<sup>a</sup>, 2005-2009</u>									
California	6.30	8.10	4.97	6.68	8.63	5.21	5.16	6.42	4.27
Greater Bay Area	6.39	8.40	4.92	7.02	9.31	5.33	5.41	6.95	4.54
San Francisco-Oakland	6.21	8.37	4.65	6.82	9.25	5.01	5.47	6.70	4.78
San Jose-Monterey	6.74	8.44	5.46	7.37	9.38	5.86	-	-	-
Los Angeles	6.06	7.69	4.87	6.59	8.43	5.23	5.38	6.75	4.37
Greater California	6.39	8.16	5.04	6.62	8.51	5.18	4.66	5.65	3.90
Connecticut	6.39	8.07	5.18	6.45	8.20	5.19	4.71	4.74	4.47
Detroit	6.97	8.63	5.90	7.56	9.10	6.61	4.81	6.76	3.51
Georgia	5.84	7.66	4.57	6.31	8.11	5.03	4.14	5.89	2.95
Atlanta	5.38	6.99	4.37	5.78	7.31	4.79	4.26	6.49	3.04
Rural Georgia	5.62	7.73	3.74	6.38	7.80	-	-	-	-
Greater Georgia	6.07	7.95	4.70	6.52	8.40	5.15	4.18	5.73	3.00
Hawaii	5.59	7.47	4.17	6.47	8.93	4.39	-	-	-
Iowa	7.03	9.21	5.48	7.06	9.24	5.51	-	-	-
Kentucky	7.30	9.22	5.91	7.49	9.35	6.13	4.53	7.21	2.67
Louisiana	6.78	9.00	5.15	7.47	9.75	5.79	4.57	6.39	3.30
New Jersey	6.55	8.09	5.46	6.91	8.51	5.80	4.36	5.25	3.61
New Mexico	5.46	6.74	4.40	5.73	7.11	4.56	-	-	-
Seattle-Puget Sound	7.02	9.05	5.45	7.26	9.35	5.61	5.44	5.73	4.67
Utah	5.95	7.48	4.63	6.02	7.54	4.70	-	-	-
9 SEER Areas <sup>b</sup>	6.40	8.24	5.07	6.75	8.62	5.36	4.71	6.24	3.70
11 SEER Areas <sup>b</sup>	6.35	8.13	5.05	6.76	8.63	5.36	4.90	6.40	3.87
13 SEER Areas <sup>b</sup>	6.35	8.13	5.05	6.76	8.64	5.37	4.87	6.39	3.82
18 SEER Areas <sup>b</sup>	6.44	8.23	5.13	6.81	8.68	5.43	4.62	6.11	3.56
Total U.S.	6.55	8.40	5.20	6.82	8.71	5.41	4.63	6.06	3.64

<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>b</sup> The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles.

The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.22  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2005-2009

Males and Females

State	Rate	SE	Rank	PD
TOTAL U.S.	6.55	0.02		
High Five States				
West Virginia	7.60 <sup>b</sup>	0.26	(01)	15.95 <sup>c</sup>
Michigan	7.35 <sup>b</sup>	0.12	(02)	12.10
Kentucky	7.30 <sup>b</sup>	0.18	(03)	11.45
Indiana	7.30 <sup>b</sup>	0.15	(04)	11.34
Wisconsin	7.28 <sup>b</sup>	0.15	(05)	11.02
Low Five States				
D.C.	5.91	0.45	(47)	-9.89
Georgia	5.84 <sup>b</sup>	0.12	(48)	-10.84
Nevada	5.73 <sup>b</sup>	0.23	(49)	-12.56
Hawaii	5.59	0.28	(50)	-14.67
New Mexico	5.46 <sup>b</sup>	0.23	(51)	-16.66 <sup>c</sup>

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	6.53	0.16	(26)	-0.31	Montana	6.64	0.35	(21)	1.30
Alaska	6.62	0.60	(22)	1.01	Nebraska	7.09	0.27	(09)	8.14
Arizona	6.00 <sup>b</sup>	0.14	(44)	-8.42	Nevada	5.73 <sup>b</sup>	0.23	(49)	-12.56
Arkansas	6.74	0.21	(20)	2.82	New Hampshire	6.03	0.30	(43)	-7.95
California	6.30 <sup>b</sup>	0.06	(32)	-3.80	New Jersey	6.55	0.12	(25)	-0.05
Colorado	5.96	0.17	(45)	-9.04	New Mexico	5.46 <sup>b</sup>	0.23	(51)	-16.66 <sup>c</sup>
Connecticut	6.39	0.18	(30)	-2.50	New York	6.16 <sup>b</sup>	0.08	(39)	-6.05
Delaware	6.47	0.37	(27)	-1.30	North Carolina	6.11 <sup>b</sup>	0.12	(42)	-6.78
D.C.	5.91	0.45	(47)	-9.89	North Dakota	6.44	0.41	(28)	-1.72
Florida	6.19 <sup>b</sup>	0.07	(38)	-5.50	Ohio	7.15 <sup>b</sup>	0.11	(07)	9.15
Georgia	5.84 <sup>b</sup>	0.12	(48)	-10.84	Oklahoma	7.20	0.19	(06)	9.90
Hawaii	5.59	0.28	(50)	-14.67	Oregon	6.91	0.18	(16)	5.47
Idaho	6.61	0.30	(23)	0.85	Pennsylvania	7.13 <sup>b</sup>	0.10	(08)	8.74
Illinois	6.83	0.10	(18)	4.25	Rhode Island	6.25	0.32	(35)	-4.68
Indiana	7.30 <sup>b</sup>	0.15	(04)	11.34	South Carolina	6.14	0.16	(41)	-6.36
Iowa	7.03	0.20	(13)	7.33	South Dakota	6.29	0.37	(34)	-4.04
Kansas	7.08	0.22	(10)	8.09	Tennessee	7.08 <sup>b</sup>	0.15	(11)	8.04
Kentucky	7.30 <sup>b</sup>	0.18	(03)	11.45	Texas	6.30	0.08	(33)	-3.88
Louisiana	6.78	0.18	(19)	3.38	Utah	5.95	0.25	(46)	-9.22
Maine	7.02	0.30	(14)	7.15	Vermont	6.21	0.42	(37)	-5.28
Maryland	6.14	0.15	(40)	-6.30	Virginia	6.40	0.13	(29)	-2.33
Massachusetts	6.35	0.13	(31)	-3.05	Washington	6.97	0.15	(15)	6.36
Michigan	7.35 <sup>b</sup>	0.12	(02)	12.10	West Virginia	7.60 <sup>b</sup>	0.26	(01)	15.95 <sup>c</sup>
Minnesota	7.04	0.16	(12)	7.41	Wisconsin	7.28 <sup>b</sup>	0.15	(05)	11.02
Mississippi	6.25	0.21	(36)	-4.70	Wyoming	6.84	0.51	(17)	4.35
Missouri	6.59	0.14	(24)	0.58					



<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
<sup>b</sup> Difference between state rate and total U.S. rate is statistically significant (p<=.0002).  
<sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.  
SE Standard error of the rate.  
PD Percent difference between state rate and total U.S. rate.  
- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.23  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2005-2009

Males

State	Rate	SE	Rank	PD
TOTAL U.S.	8.40	0.04		
High Five States				
Indiana	9.72 <sup>b</sup>	0.27	(01)	15.76 <sup>c</sup>
Kansas	9.63	0.40	(02)	14.74
Minnesota	9.57 <sup>b</sup>	0.30	(03)	14.03
Ohio	9.43 <sup>b</sup>	0.19	(04)	12.31
Wisconsin	9.41 <sup>b</sup>	0.27	(05)	12.10
Low Five States				
Hawaii	7.47	0.48	(47)	-11.04
Arizona	7.47 <sup>b</sup>	0.23	(48)	-11.05
North Dakota	7.44	0.68	(49)	-11.34
New Mexico	6.74 <sup>b</sup>	0.39	(50)	-19.73 <sup>c</sup>
Nevada	6.67 <sup>b</sup>	0.36	(51)	-20.61 <sup>c</sup>

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	8.28	0.29	(27)	-1.34	Montana	8.14	0.58	(28)	-2.99
Alaska	7.89	1.02	(40)	-6.01	Nebraska	9.02	0.47	(14)	7.38
Arizona	7.47 <sup>b</sup>	0.23	(48)	-11.05	Nevada	6.67 <sup>b</sup>	0.36	(51)	-20.61 <sup>c</sup>
Arkansas	8.77	0.36	(19)	4.47	New Hampshire	7.68	0.52	(43)	-8.58
California	8.10	0.11	(30)	-3.56	New Jersey	8.09	0.21	(31)	-3.59
Colorado	8.00	0.31	(36)	-4.71	New Mexico	6.74 <sup>b</sup>	0.39	(50)	-19.73 <sup>c</sup>
Connecticut	8.07	0.32	(33)	-3.93	New York	7.95	0.14	(38)	-5.25
Delaware	8.42	0.65	(22)	0.34	North Carolina	7.63 <sup>b</sup>	0.21	(45)	-9.16
D.C.	9.40	0.92	(06)	11.95	North Dakota	7.44	0.68	(49)	-11.34
Florida	7.77 <sup>b</sup>	0.12	(42)	-7.43	Ohio	9.43 <sup>b</sup>	0.19	(04)	12.31
Georgia	7.66	0.23	(44)	-8.77	Oklahoma	8.93	0.33	(16)	6.34
Hawaii	7.47	0.48	(47)	-11.04	Oregon	8.59	0.32	(21)	2.35
Idaho	8.07	0.51	(32)	-3.84	Pennsylvania	9.21 <sup>b</sup>	0.17	(09)	9.75
Illinois	8.85	0.19	(17)	5.38	Rhode Island	8.75	0.60	(20)	4.25
Indiana	9.72 <sup>b</sup>	0.27	(01)	15.76 <sup>c</sup>	South Carolina	7.97	0.29	(37)	-5.05
Iowa	9.21	0.35	(10)	9.68	South Dakota	7.80	0.63	(41)	-7.04
Kansas	9.63	0.40	(02)	14.74	Tennessee	9.25	0.27	(07)	10.21
Kentucky	9.22	0.32	(08)	9.79	Texas	8.06	0.14	(34)	-3.96
Louisiana	9.00	0.32	(15)	7.21	Utah	7.48	0.42	(46)	-10.94
Maine	9.15	0.53	(12)	9.00	Vermont	8.06	0.76	(35)	-4.03
Maryland	7.93	0.27	(39)	-5.56	Virginia	8.33	0.24	(24)	-0.78
Massachusetts	8.30	0.24	(25)	-1.16	Washington	8.79	0.26	(18)	4.71
Michigan	9.19 <sup>b</sup>	0.21	(11)	9.46	West Virginia	9.14	0.45	(13)	8.85
Minnesota	9.57 <sup>b</sup>	0.30	(03)	14.03	Wisconsin	9.41 <sup>b</sup>	0.27	(05)	12.10
Mississippi	8.29	0.38	(26)	-1.28	Wyoming	8.11	0.86	(29)	-3.36
Missouri	8.38	0.25	(23)	-0.14					



<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
<sup>b</sup> Difference between state rate and total U.S. rate is statistically significant (p<=.0002).  
<sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.  
SE Standard error of the rate.  
PD Percent difference between state rate and total U.S. rate.  
- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.24  
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death<sup>a</sup> Rates By State, All Races, 2005-2009

Females

State	Rate	SE	Rank	PD
TOTAL U.S.	5.20	0.02		
High Five States				
West Virginia	6.37 <sup>b</sup>	0.32	(01)	22.62 <sup>c</sup>
Michigan	6.06 <sup>b</sup>	0.14	(02)	16.64 <sup>c</sup>
Wyoming	5.95	0.64	(03)	14.45
Oklahoma	5.93	0.23	(04)	14.12
Kentucky	5.91	0.21	(05)	13.75
Low Five States				
Georgia	4.57 <sup>b</sup>	0.14	(47)	-12.09
New Mexico	4.40	0.28	(48)	-15.39 <sup>c</sup>
Colorado	4.39 <sup>b</sup>	0.19	(49)	-15.48 <sup>c</sup>
Hawaii	4.17	0.32	(50)	-19.85 <sup>c</sup>
D.C.	3.48 <sup>b</sup>	0.44	(51)	-33.00 <sup>c</sup>

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	5.32	0.19	(23)	2.34	Montana	5.37	0.42	(21)	3.38
Alaska	5.75	0.76	(06)	10.73	Nebraska	5.71	0.32	(08)	9.90
Arizona	4.78	0.16	(43)	-8.03	Nevada	4.81	0.28	(42)	-7.51
Arkansas	5.21	0.24	(25)	0.31	New Hampshire	4.96	0.36	(36)	-4.57
California	4.97	0.07	(34)	-4.28	New Jersey	5.46	0.14	(18)	5.16
Colorado	4.39 <sup>b</sup>	0.19	(49)	-15.48 <sup>c</sup>	New Mexico	4.40	0.28	(48)	-15.39 <sup>c</sup>
Connecticut	5.18	0.21	(27)	-0.33	New York	4.89	0.09	(38)	-5.87
Delaware	4.96	0.43	(37)	-4.60	North Carolina	5.00	0.14	(31)	-3.70
D.C.	3.48 <sup>b</sup>	0.44	(51)	-33.00 <sup>c</sup>	North Dakota	5.53	0.51	(14)	6.45
Florida	4.89 <sup>b</sup>	0.09	(39)	-5.98	Ohio	5.55	0.12	(12)	6.90
Georgia	4.57 <sup>b</sup>	0.14	(47)	-12.09	Oklahoma	5.93	0.23	(04)	14.12
Hawaii	4.17	0.32	(50)	-19.85 <sup>c</sup>	Oregon	5.65	0.22	(09)	8.82
Idaho	5.44	0.37	(20)	4.75	Pennsylvania	5.63 <sup>b</sup>	0.11	(10)	8.28
Illinois	5.47	0.12	(17)	5.20	Rhode Island	4.58	0.36	(46)	-11.84
Indiana	5.61	0.17	(11)	7.97	South Carolina	4.81	0.19	(41)	-7.35
Iowa	5.48	0.23	(15)	5.48	South Dakota	5.07	0.44	(30)	-2.44
Kansas	5.25	0.25	(24)	1.02	Tennessee	5.47	0.17	(16)	5.24
Kentucky	5.91	0.21	(05)	13.75	Texas	5.00	0.09	(33)	-3.86
Louisiana	5.15	0.20	(28)	-0.87	Utah	4.63	0.29	(45)	-10.86
Maine	5.46	0.35	(19)	5.04	Vermont	4.96	0.50	(35)	-4.53
Maryland	4.85	0.17	(40)	-6.62	Virginia	5.00	0.15	(32)	-3.77
Massachusetts	5.08	0.15	(29)	-2.34	Washington	5.54	0.18	(13)	6.68
Michigan	6.06 <sup>b</sup>	0.14	(02)	16.64 <sup>c</sup>	West Virginia	6.37 <sup>b</sup>	0.32	(01)	22.62 <sup>c</sup>
Minnesota	5.19	0.18	(26)	-0.14	Wisconsin	5.73	0.18	(07)	10.32
Mississippi	4.76	0.24	(44)	-8.43	Wyoming	5.95	0.64	(03)	14.45
Missouri	5.32	0.17	(22)	2.41					



<sup>a</sup> US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).  
<sup>b</sup> Difference between state rate and total U.S. rate is statistically significant (p<=.0002).  
<sup>c</sup> Absolute percent difference between state rate and total U.S. rate is 15% or more.  
SE Standard error of the rate.  
PD Percent difference between state rate and total U.S. rate.  
- Statistic not shown. Rate based on less than 16 cases for the time interval.



Table 19.25  
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2009  
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <19 <sup>e</sup>	0 to <34 <sup>e</sup>	>=34 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	193,568	124,952	73,118	40,328	23,808	13,206	425,784	474,455	9,881	484,336
	Males	101,809	64,597	37,822	20,781	12,282	6,865	221,874	246,926	5,185	252,111
	Females	91,759	60,355	35,296	19,547	11,526	6,341	203,910	227,529	4,696	232,225
White <sup>b</sup>	Both Sexes	169,344	111,105	64,658	36,119	21,607	12,076	375,558	419,930	10,218	430,148
	Males	89,651	57,853	33,336	18,717	11,169	6,255	196,674	219,545	5,745	225,290
	Females	79,693	53,252	31,322	17,402	10,438	5,821	178,884	200,385	4,473	204,858
Black <sup>b</sup>	Both Sexes	15,176	8,849	5,327	2,662	1,414	748	31,735	34,493	788	35,281
	Males	7,256	4,279	2,863	1,262	730	392	15,520	16,913	326	17,239
	Females	7,920	4,570	2,464	1,400	684	356	16,215	17,580	462	18,042
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	5,134	3,241	1,818	+	+	+	11,000	+	+	+
	Males	2,740	1,632	930	+	+	+	5,705	+	+	+
	Females	2,394	1,609	888	+	+	+	5,295	+	+	+
Hispanic <sup>d</sup>	Both Sexes	13,379	8,080	4,315	+	+	+	27,683	+	+	+
	Males	7,003	4,207	2,320	+	+	+	14,463	+	+	+
	Females	6,376	3,873	1,995	+	+	+	13,220	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2009, of the SEER 11 population diagnosed in the previous 19 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted <sup>f</sup>
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.1153%	0.0026%	0.0115%	0.0208%	0.0396%	0.0862%	0.1728%	0.3318%	0.5039%	0.5486%	0.1155%
	Males	0.1221%	0.0033%	0.0150%	0.0252%	0.0458%	0.1019%	0.1966%	0.3775%	0.5621%	0.6296%	0.1323%
	Females	0.1087%	0.0018%	0.0077%	0.0162%	0.0332%	0.0705%	0.1499%	0.2904%	0.4576%	0.5035%	0.1010%
White <sup>c</sup>	Both Sexes	0.1277%	0.0027%	0.0117%	0.0212%	0.0409%	0.0901%	0.1830%	0.3570%	0.5473%	0.5864%	0.1232%
	Males	0.1347%	0.0036%	0.0154%	0.0261%	0.0476%	0.1061%	0.2070%	0.4044%	0.6074%	0.6742%	0.1407%
	Females	0.1207%	0.0018%	0.0077%	0.0159%	0.0337%	0.0735%	0.1592%	0.3127%	0.4983%	0.5374%	0.1077%
Black <sup>c</sup>	Both Sexes	0.0713%	0.0024%	0.0110%	0.0205%	0.0422%	0.0831%	0.1485%	0.2386%	0.2937%	0.2691%	0.0840%
	Males	0.0753%	0.0029%	0.0142%	0.0240%	0.0511%	0.0989%	0.1722%	0.2720%	0.2816%	0.3000%	0.0941%
	Females	0.0677%	0.0019%	0.0077%	0.0172%	0.0344%	0.0693%	0.1286%	0.2129%	0.3021%	0.2547%	0.0757%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0746%	0.0017%	0.0097%	0.0181%	0.0262%	0.0574%	0.1129%	0.1978%	0.3356%	0.3810%	0.0763%
	Males	0.0793%	0.0022%	0.0119%	0.0208%	0.0274%	0.0669%	0.1273%	0.2261%	0.3958%	0.4352%	0.0879%
	Females	0.0702%	-	0.0073%	0.0154%	0.0250%	0.0486%	0.1004%	0.1737%	0.2900%	0.3474%	0.0670%
Hispanic <sup>d</sup>	Both Sexes	0.0547%	0.0023%	0.0088%	0.0160%	0.0299%	0.0652%	0.1331%	0.2453%	0.3831%	0.3971%	0.0874%
	Males	0.0552%	0.0030%	0.0115%	0.0196%	0.0350%	0.0733%	0.1456%	0.2524%	0.3854%	0.4209%	0.0934%
	Females	0.0541%	0.0015%	0.0060%	0.0118%	0.0239%	0.0562%	0.1210%	0.2392%	0.3813%	0.3832%	0.0816%

<sup>a</sup> US 2009 cancer prevalence counts are based on 2009 cancer prevalence proportions from the SEER registries and 1/1/2009 US population estimates based on the average of 2008 and 2009 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

<sup>b c d</sup> Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia.

<sup>e</sup> Maximum limited-duration prevalence: 34 years for 1975-2009 SEER 9 data; 19 years for 1990-2009 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 34 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <34 and >=34. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 19.26  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2001-2009

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	35.1	251,928	-0.2	5.8	12,225	0.7	23.5	107,693	-0.6*	155.1	132,010	0.0
1 Hodgkin Lymphoma	2.8	20,498	0.3	1.2	2,562	2.1*	3.2	14,384	-0.3	4.2	3,552	1.5
2 Non-Hodgkin lymphoma	31.1	223,232	-0.1	4.5	9,587	0.4	19.7	90,492	-0.4*	144.8	123,153	0.1
2(a) Non-Hodgkin lymphoma, B-cell	28.4	203,314	0.1	3.2	6,842	2.7*	17.6	81,196	-0.3	135.5	115,276	0.2
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.2	8,880	3.7*	2.5	5,438	3.3*	0.6	2,626	3.5*	1.0	816	6.4*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	26.0	185,751	-0.1	0.6	1,326	0.0	16.4	75,589	-0.4	128.0	108,836	0.1
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	6.4	45,522	-1.2*	0.0	22	-	3.2	15,170	-1.6*	35.6	30,330	-1.0
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	5.6	40,095	-1.6*	0.0	18	-	2.8	13,143	-1.8*	31.6	26,934	-1.4*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	184	-5.7	-	-	-	0.0	49	-	0.2	131	-4.7
2(a) 2.1.3. Mantle-cell lymphoma	0.7	5,243	1.9*	0.0	0	-	0.4	1,978	0.3	3.9	3,265	2.7*
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.6	4,420	-2.5*	-	-	-	0.3	1,340	-2.4*	3.6	3,077	-2.6*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.3	1,960	0.6	-	-	-	0.1	619	-0.6	1.6	1,340	1.1
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.3	2,460	-4.9*	-	-	-	0.2	721	-3.8*	2.0	1,737	-5.3*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	6.8	48,940	0.0	0.3	576	0.1	4.7	21,162	-0.8*	31.9	27,202	0.5
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	6.8	48,536	-0.2	0.3	561	-0.6	4.6	20,844	-1.1*	31.9	27,131	0.5
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	51	-	0.0	0	-	0.0	19	-	0.0	32	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	72	-	0.0	0	-	0.0	54	-	0.0	18	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	281	18.9*	-	-	-	0.1	245	18.8*	0.0	21	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.4	2,981	1.6	0.3	595	-0.6	0.4	1,700	3.3*	0.8	686	-0.4
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.8	13,252	2.4*	0.0	58	-	1.2	5,584	1.2*	9.0	7,610	3.2*
2(a) 2.5.1. Splenic MZL	0.1	924	3.4*	0.0	0	-	0.1	364	0.7	0.7	560	5.0*
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	1.1	8,245	1.1	0.0	40	-	0.8	3,704	0.6	5.3	4,501	1.4
2(a) 2.5.3. Nodal MZL	0.6	4,083	5.1*	0.0	18	-	0.3	1,516	2.7	3.0	2,549	6.3*
2(a) 2.6. Follicular lymphoma	3.7	26,618	0.5	0.0	65	-	3.0	13,768	-0.1	15.1	12,785	1.0
2(a) 2.7. Hairy-cell leukemia	0.3	2,142	-1.3	0.0	0	-	0.3	1,350	-1.4	0.9	792	-1.1
2(a) 2.8. Plasma cell neoplasms	5.9	41,836	0.0	-	-	-	3.3	15,499	0.2	31.0	26,330	-0.1
2(a) 2.8.1. Plasmacytoma	0.4	2,675	1.9	-	-	-	0.3	1,329	0.6	1.6	1,341	3.1*
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	5.5	39,161	-0.2	-	-	-	3.0	14,170	0.2	29.4	24,989	-0.3
2(a) 2.9. Heavy chain disease	0.0	40	-	0.0	0	-	0.0	16	-	0.0	24	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	1.2	8,683	1.9*	0.0	78	-	0.6	2,981	-0.6	6.6	5,624	3.1*

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.26 - continued  
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
 SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2001-2009

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.1	15,015	0.4	0.7	1,575	0.1	1.7	7,761	-0.1	6.7	5,679	1.1*
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.3	2,025	1.0	0.5	1,082	1.3	0.2	804	0.6	0.2	139	0.5
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.8	12,834	0.4	0.2	488	-2.5	1.5	6,883	-0.2	6.4	5,463	1.3*
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.5	3,363	0.0	0.0	77	-	0.4	2,012	-0.7	1.5	1,274	0.6
2(b) 2.1.1. Mycosis fungoides	0.4	3,272	-0.2	0.0	77	-	0.4	1,981	-0.7	1.4	1,214	0.3
2(b) 2.1.2. Sezary syndrome	0.0	91	-	0.0	0	-	0.0	31	-	0.1	60	-
2(b) 2.2. Peripheral T-cell lymphoma	1.1	8,276	0.2	0.2	382	-3.9	0.9	4,201	-0.5	4.4	3,693	1.3*
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	0.4	2,896	-0.5	0.0	70	-	0.3	1,386	-2.3*	1.7	1,440	1.3
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	900	9.6*	-	-	-	0.1	359	8.2*	0.6	539	10.4*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	97	-	-	-	-	0.0	59	-	0.0	25	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.3	1,886	-3.3*	0.1	232	-5.5	0.2	1,048	-1.9	0.7	606	-4.3*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	55	-	-	-	-	0.0	39	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	85	-	0.0	0	-	0.0	42	-	0.1	43	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	0.2	1,613	-1.4	0.0	22	-	0.2	863	-1.9	0.9	728	-1.0
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	744	3.4	0.0	31	-	0.1	405	4.3	0.4	308	2.7
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.0	267	-5.2	-	-	-	0.0	130	-	0.2	130	-
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	0.1	519	4.4	0.0	21	-	0.1	366	5.4*	0.2	132	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	194	9.6*	-	-	-	0.0	79	-	0.1	114	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	215	5.4	0.0	0	-	0.0	95	-	0.1	120	-
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	0.0	156	-6.4	-	-	-	0.0	74	-	0.1	77	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.7	4,903	-8.7*	0.5	1,170	-12.2*	0.3	1,535	-8.3*	2.6	2,198	-7.2*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.3	2,038	-11.9*	0.5	1,146	-12.3*	0.1	520	-11.9*	0.4	372	-10.2*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	111	-	-	-	-	0.0	31	-	0.1	78	-
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	0.4	2,754	-6.5*	0.0	22	-	0.2	984	-6.2*	2.0	1,748	-6.6*
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	1.7	12,943	0.7	3.6	7,666	0.6	0.9	3,950	0.8	1.6	1,327	0.8
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	115	-2.3	-	-	-	0.0	58	-	0.1	55	-
4 Lymphoid neoplasm, NOS <sup>c</sup>	1.1	8,083	-5.1*	0.0	74	-	0.6	2,759	-6.5*	6.1	5,250	-4.5*

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2001-2009

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	43.3	138,936	-0.2	6.6	7,137	0.8	28.1	63,081	-0.7*	197.7	68,718	0.1
1 Hodgkin Lymphoma	3.1	11,179	0.2	1.3	1,372	1.8	3.6	7,953	-0.6	5.2	1,854	2.0
2 Non-Hodgkin lymphoma	38.8	123,489	0.0	5.2	5,719	0.5	23.7	53,430	-0.5*	185.0	64,340	0.3
2(a) Non-Hodgkin lymphoma, B-cell	35.3	111,854	0.2	3.6	3,944	2.6*	21.2	47,829	-0.4	172.8	60,081	0.4
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.3	4,826	3.6*	2.7	2,992	3.2*	0.6	1,458	3.0*	1.1	376	7.5*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	32.6	102,533	-0.1	0.8	897	0.3	19.8	44,669	-0.5	163.7	56,967	0.2
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	9.0	27,593	-1.1*	-	-	-	4.4	9,985	-1.7*	50.7	17,596	-0.8
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	7.8	23,791	-1.6*	-	-	-	3.7	8,476	-2.0*	44.2	15,304	-1.4*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	117	-	-	-	-	0.0	31	-	0.2	85	-
2(a) 2.1.3. Mantle-cell lymphoma	1.2	3,685	2.3*	0.0	0	-	0.6	1,478	0.4	6.3	2,207	3.3*
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.9	2,565	-3.1*	-	-	-	0.3	774	-3.3*	5.2	1,790	-3.0*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.4	1,084	0.6	0.0	0	-	0.2	352	-1.8	2.1	732	1.4
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.5	1,481	-5.7*	-	-	-	0.2	422	-4.6*	3.1	1,058	-5.9*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	8.3	26,392	0.1	0.3	332	0.0	5.7	12,761	-0.8	38.4	13,299	0.7*
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	8.2	26,189	0.0	0.3	329	-0.2	5.6	12,600	-1.0*	38.3	13,260	0.7*
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	28	-	0.0	0	-	-	-	-	0.0	16	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	63	-	0.0	0	-	0.0	50	-	-	-	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	112	-	-	-	-	0.0	99	-	-	-	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.6	2,166	1.8*	0.4	465	-0.3	0.6	1,315	3.3*	1.1	386	-0.3
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.9	6,076	3.2*	0.0	35	-	1.2	2,668	2.0*	9.7	3,373	3.8*
2(a) 2.5.1. Splenic MZL	0.1	436	3.8	0.0	0	-	0.1	177	0.0	0.7	259	6.2
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	1.2	3,707	1.4	0.0	22	-	0.8	1,713	1.6	5.6	1,972	1.3
2(a) 2.5.3. Nodal MZL	0.6	1,933	6.5*	-	-	-	0.3	778	3.3	3.3	1,142	7.9*
2(a) 2.6. Follicular lymphoma	4.0	13,135	0.4	0.0	47	-	3.2	7,195	-0.5	16.6	5,893	1.2
2(a) 2.7. Hairy-cell leukemia	0.5	1,693	-0.6	0.0	0	-	0.5	1,097	-0.7	1.7	596	-0.4
2(a) 2.8. Plasma cell neoplasms	7.4	22,886	0.2	-	-	-	3.9	8,866	0.3	40.2	14,015	0.2
2(a) 2.8.1. Plasmacytoma	0.5	1,674	1.7	-	-	-	0.4	882	0.2	2.2	788	3.1
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	6.9	21,212	0.1	-	-	-	3.5	7,984	0.3	38.0	13,227	0.0
2(a) 2.9. Heavy chain disease	0.0	27	-	0.0	0	-	-	-	-	0.1	19	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	1.5	4,495	2.2*	0.1	55	-	0.8	1,702	-1.3	8.0	2,738	3.7*

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27 - continued  
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
 SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2001-2009

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.7	8,988	0.2	1.0	1,100	1.6*	2.1	4,651	-0.2	9.2	3,237	0.2
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.4	1,423	1.8	0.7	796	2.3	0.2	549	0.7	0.2	78	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	2.3	7,477	0.0	0.3	300	-0.8	1.8	4,063	-0.2	8.9	3,114	0.3
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.6	1,927	-0.6	0.0	33	-	0.5	1,105	0.8	2.2	789	-2.3*
2(b) 2.1.1. Mycosis fungoides	0.6	1,874	-0.7	0.0	33	-	0.5	1,089	0.8	2.1	752	-2.6*
2(b) 2.1.2. Sezary syndrome	0.0	53	-	0.0	0	-	0.0	16	-	0.1	37	-
2(b) 2.2. Peripheral T-cell lymphoma	1.5	4,856	-0.2	0.2	246	-1.9	1.1	2,546	-1.2	5.9	2,064	0.9
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	0.5	1,724	-0.1	0.0	44	-	0.4	877	-2.3*	2.3	803	2.1
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	461	7.0*	-	-	-	0.1	196	6.0*	0.8	264	7.5*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	28	-	-	-	-	-	-	-	-	-	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.3	1,185	-4.1*	0.1	157	-2.4	0.3	681	-3.3	1.0	347	-5.4*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	39	-	-	-	-	0.0	24	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	51	-	0.0	0	-	0.0	25	-	0.1	26	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	0.3	941	-0.7	-	-	-	0.2	512	-2.2	1.2	416	0.4
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	427	2.6	0.0	18	-	0.1	216	4.7*	0.6	193	0.5
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.0	135	-	-	-	-	0.0	75	-	0.2	55	-
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	0.1	346	5.9	0.0	16	-	0.1	251	6.5*	0.2	79	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	95	-	0.0	0	-	0.0	31	-	0.2	64	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	118	-	0.0	0	-	0.0	55	-	0.2	63	-
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	0.0	88	-	-	-	-	0.0	39	-	0.1	45	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.8	2,647	-9.0*	0.6	675	-12.5*	0.4	950	-8.4*	3.0	1,022	-7.7*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.3	1,139	-11.8*	0.6	658	-12.5*	0.1	302	-11.8*	0.5	179	-9.3
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	67	-	-	-	-	0.0	19	-	0.1	47	-
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	0.5	1,441	-7.0*	0.0	16	-	0.3	629	-6.4*	2.3	796	-7.2*
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	2.0	7,388	0.7	4.1	4,446	0.6	1.0	2,309	0.4	1.8	633	1.5
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	63	-	-	-	-	0.0	37	-	0.1	25	-
4 Lymphoid neoplasm, NOS <sup>c</sup>	1.4	4,205	-5.0*	0.0	45	-	0.7	1,661	-6.4*	7.4	2,499	-4.4*

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>  
SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2001-2009

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	28.6	112,992	-0.3	4.9	5,088	0.7	19.2	44,612	-0.4	126.1	63,292	-0.3
1 Hodgkin Lymphoma	2.5	9,319	0.5	1.2	1,190	2.3	2.9	6,431	0.0	3.4	1,698	0.9
2 Non-Hodgkin lymphoma	25.2	99,743	-0.2	3.7	3,868	0.2	15.8	37,062	-0.3	117.4	58,813	-0.1
2(a) Non-Hodgkin lymphoma, B-cell	23.0	91,460	0.0	2.8	2,898	2.9*	14.2	33,367	-0.2	110.2	55,195	-0.1
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.1	4,054	3.8*	2.3	2,446	3.4*	0.5	1,168	4.0*	0.9	440	5.7*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	20.9	83,218	-0.3	0.4	429	-0.6	13.1	30,920	-0.3	103.6	51,869	-0.2
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	4.4	17,929	-1.5*	-	-	-	2.2	5,185	-1.4	25.2	12,734	-1.5*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	4.0	16,304	-1.7*	-	-	-	1.9	4,667	-1.5	23.0	11,630	-1.7*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	67	-	-	-	-	0.0	18	-	0.1	46	-
2(a) 2.1.3. Mantle-cell lymphoma	0.4	1,558	0.7	0.0	0	-	0.2	500	-0.3	2.1	1,058	1.2
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.5	1,855	-1.7*	-	-	-	0.2	566	-1.2	2.6	1,287	-2.0*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.2	876	0.7	-	-	-	0.1	267	1.0	1.2	608	0.5
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.2	979	-3.9*	-	-	-	0.1	299	-3.1	1.4	679	-4.3*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	5.7	22,548	-0.2	0.2	244	-0.1	3.6	8,401	-0.8	27.6	13,903	0.2
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	5.6	22,347	-0.3	0.2	232	-1.4	3.5	8,244	-1.2*	27.6	13,871	0.2
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	23	-	0.0	0	-	-	-	-	0.0	16	-
2(a) 2.3.3. Primary effusion lymphoma	-	-	-	0.0	0	-	-	-	-	-	-	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	169	-	-	-	-	0.1	146	-	-	-	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.2	815	0.9	0.1	130	-	0.2	385	2.8	0.6	300	-0.3
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.8	7,176	1.8*	0.0	23	-	1.2	2,916	0.4	8.5	4,237	2.7*
2(a) 2.5.1. Splenic MZL	0.1	488	2.7	0.0	0	-	0.1	187	1.4	0.6	301	3.4
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	1.1	4,538	0.7	0.0	18	-	0.8	1,991	-0.2	5.1	2,529	1.4
2(a) 2.5.3. Nodal MZL	0.5	2,150	4.0*	-	-	-	0.3	738	2.1	2.8	1,407	5.1*
2(a) 2.6. Follicular lymphoma	3.4	13,483	0.5	0.0	18	-	2.8	6,573	0.3	14.0	6,892	0.8
2(a) 2.7. Hairy-cell leukemia	0.1	449	-4.4*	0.0	0	-	0.1	253	-4.4	0.4	196	-3.8
2(a) 2.8. Plasma cell neoplasms	4.8	18,950	-0.4	-	-	-	2.8	6,633	0.1	24.7	12,315	-0.6
2(a) 2.8.1. Plasmacytoma	0.3	1,001	2.4	-	-	-	0.2	447	1.3	1.1	553	3.1
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	4.5	17,949	-0.5	-	-	-	2.6	6,186	0.0	23.6	11,762	-0.8*
2(a) 2.9. Heavy chain disease	-	-	-	0.0	0	-	-	-	-	-	-	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	1.0	4,188	1.6	0.0	23	-	0.5	1,279	0.2	5.7	2,886	2.2

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28 - continued  
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes  
 SEER<sup>b</sup> Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2001-2009

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	1.6	6,027	0.5	0.5	475	-3.0	1.4	3,110	-0.1	4.9	2,442	2.1*
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.2	602	-0.9	0.3	286	-1.2	0.1	255	0.2	0.1	61	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.4	5,357	0.7*	0.2	188	-5.7*	1.2	2,820	-0.1	4.7	2,349	2.4*
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.4	1,436	0.3	0.0	44	-	0.4	907	-2.5*	1.0	485	5.6*
2(b) 2.1.1. Mycosis fungoides	0.4	1,398	0.2	0.0	44	-	0.4	892	-2.4*	0.9	462	5.4*
2(b) 2.1.2. Sezary syndrome	0.0	38	-	0.0	0	-	-	-	-	0.0	23	-
2(b) 2.2. Peripheral T-cell lymphoma	0.9	3,420	0.5	0.1	136	-	0.7	1,655	0.5	3.3	1,629	1.4
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	0.3	1,172	-1.1	0.0	26	-	0.2	509	-2.4	1.3	637	0.2
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	439	12.2*	-	-	-	0.1	163	-	0.6	275	13.2*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	69	-	-	-	-	0.0	44	-	-	-	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.2	701	-2.2	0.1	75	-	0.2	367	0.8	0.5	259	-3.2
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	16	-	-	-	-	-	-	-	0.0	0	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	34	-	0.0	0	-	0.0	17	-	0.0	17	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	0.2	672	-2.6*	-	-	-	0.2	351	-1.5	0.6	312	-3.8
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	317	4.1	-	-	-	0.1	189	4.4	0.2	115	-
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.0	132	-	-	-	-	0.0	55	-	0.2	75	-
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	0.0	173	1.0	-	-	-	0.1	115	-	0.1	53	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	99	-	-	-	-	0.0	48	-	0.1	50	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	97	-	0.0	0	-	0.0	40	-	0.1	57	-
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	0.0	68	-	-	-	-	0.0	35	-	0.1	32	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.6	2,256	-8.5*	0.5	495	-11.8*	0.3	585	-8.1*	2.3	1,176	-7.1*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.2	899	-11.9*	0.5	488	-12.0*	0.1	218	-12.0*	0.4	193	-11.6*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	44	-	-	-	-	-	-	-	0.1	31	-
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	0.3	1,313	-6.2*	-	-	-	0.2	355	-5.8*	1.9	952	-6.3*
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	1.5	5,555	0.7	3.1	3,220	0.5	0.7	1,641	1.2	1.4	694	0.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	52	-	-	-	-	0.0	21	-	0.1	30	-
4 Lymphoid neoplasm, NOS <sup>c</sup>	0.9	3,878	-5.1*	0.0	29	-	0.5	1,098	-6.6*	5.2	2,751	-4.7*

The APC is the Annual Percent Change over the time interval.

<sup>a</sup> Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.29  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2002-2008

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
Lymphoid Neoplasm	163,213	66.6 ( 66.3 , 66.9 )	87.7 ( 86.9 , 88.4 )	74.5 ( 74.1 , 74.9 )	55.5 ( 55.0 , 56.1 )				
1 Hodgkin Lymphoma	14,733	84.7 ( 84.0 , 85.4 )	95.9 ( 94.7 , 96.9 )	88.9 ( 88.2 , 89.7 )	50.9 ( 47.8 , 53.9 )				
2 Non-Hodgkin lymphoma	143,726	65.3 ( 64.9 , 65.6 )	85.5 ( 84.6 , 86.4 )	72.4 ( 72.0 , 72.9 )	56.3 ( 55.8 , 56.9 )				
2(a) Non-Hodgkin lymphoma, B-cell	130,855	65.7 ( 65.4 , 66.1 )	87.2 ( 86.1 , 88.2 )	73.5 ( 73.0 , 73.9 )	57.0 ( 56.4 , 57.6 )				
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	6,641	66.1 ( 64.7 , 67.4 )	87.5 ( 86.3 , 88.6 )	31.0 ( 28.5 , 33.6 )	11.5 ( 8.0 , 15.7 )				
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	118,868	65.7 ( 65.3 , 66.1 )	86.3 ( 83.9 , 88.4 )	75.0 ( 74.5 , 75.4 )	57.1 ( 56.5 , 57.7 )				
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	28,217	75.1 ( 74.3 , 75.9 )	- ( - , - )	84.1 ( 83.1 , 85.0 )	69.4 ( 68.2 , 70.5 )				
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	24,944	78.0 ( 77.1 , 78.8 )	- ( - , - )	87.0 ( 86.0 , 87.9 )	72.3 ( 71.0 , 73.5 )				
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	114	38.6 ( 26.9 , 50.1 )	- ( - , - )	45.0 ( 23.6 , 64.3 )	35.8 ( 21.7 , 50.2 )				
2(a) 2.1.3. Mantle-cell lymphoma	3,159	53.9 ( 51.4 , 56.3 )	- ( - , - )	64.8 ( 61.3 , 68.0 )	45.3 ( 41.9 , 48.7 )				
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,634	76.0 ( 73.3 , 78.5 )	- ( - , - )	83.3 ( 79.8 , 86.3 )	71.7 ( 67.8 , 75.2 )				
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,152	75.2 ( 70.9 , 79.0 )	- ( - , - )	81.5 ( 75.9 , 86.0 )	71.2 ( 65.0 , 76.4 )				
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,482	76.7 ( 72.9 , 79.9 )	- ( - , - )	84.7 ( 79.9 , 88.4 )	72.2 ( 66.9 , 76.7 )				
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	31,885	60.0 ( 59.3 , 60.7 )	83.4 ( 79.3 , 86.7 )	69.4 ( 68.5 , 70.2 )	50.3 ( 49.2 , 51.4 )				
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	31,599	59.9 ( 59.2 , 60.6 )	84.2 ( 80.1 , 87.5 )	69.3 ( 68.4 , 70.2 )	50.3 ( 49.2 , 51.4 )				
2(a) 2.3.2. Intravascular large B-cell lymphoma	31	43.2 ( 22.4 , 62.4 )	- ( - , - )	- ( - , - )	- ( - , - )				
2(a) 2.3.3. Primary effusion lymphoma	51	24.7 ( 12.8 , 38.7 )	- ( - , - )	28.7 ( 15.1 , 43.8 )	- ( - , - )				
2(a) 2.3.4. Mediastinal large B-cell lymphoma	204	83.3 ( 75.5 , 88.8 )	- ( - , - )	88.8 ( 82.0 , 93.1 )	- ( - , - )				
2(a) 2.4. Burkitt lymphoma/leukemia	2,057	55.9 ( 53.5 , 58.3 )	86.8 ( 83.3 , 89.7 )	52.4 ( 49.2 , 55.5 )	29.6 ( 23.7 , 35.7 )				
2(a) 2.5. Marginal-zone lymphoma (MZL)	8,187	88.7 ( 87.3 , 89.9 )	100.0 ( - , - )	93.2 ( 92.0 , 94.3 )	84.0 ( 81.6 , 86.2 )				
2(a) 2.5.1. Splenic MZL	584	85.7 ( 79.8 , 89.9 )	- ( - , - )	91.3 ( 85.9 , 94.7 )	80.1 ( 69.5 , 87.3 )				
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	5,137	92.3 ( 90.6 , 93.7 )	100.0 ( - , - )	95.3 ( 93.8 , 96.5 )	88.8 ( 85.5 , 91.3 )				
2(a) 2.5.3. Nodal MZL	2,466	81.8 ( 79.1 , 84.2 )	- ( - , - )	88.4 ( 85.5 , 90.8 )	76.2 ( 71.8 , 80.0 )				
2(a) 2.6. Follicular lymphoma	17,762	84.6 ( 83.7 , 85.4 )	95.6 ( 82.8 , 98.9 )	89.2 ( 88.3 , 90.0 )	78.2 ( 76.5 , 79.8 )				
2(a) 2.7. Hairy-cell leukemia	1,442	94.8 ( 92.0 , 96.7 )	- ( - , - )	97.8 ( 96.1 , 98.8 )	86.0 ( 77.8 , 91.4 )				
2(a) 2.8. Plasma cell neoplasms	26,656	40.9 ( 40.1 , 41.7 )	- ( - , - )	54.0 ( 52.8 , 55.1 )	31.2 ( 30.1 , 32.3 )				
2(a) 2.8.1. Plasmacytoma	1,662	64.1 ( 60.9 , 67.2 )	- ( - , - )	77.2 ( 73.5 , 80.4 )	47.1 ( 41.6 , 52.3 )				
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	24,994	39.4 ( 38.5 , 40.2 )	- ( - , - )	51.8 ( 50.6 , 53.1 )	30.4 ( 29.3 , 31.5 )				
2(a) 2.9. Heavy chain disease	28	64.2 ( 38.9 , 81.2 )	- ( - , - )	- ( - , - )	- ( - , - )				
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	5,346	66.4 ( 64.5 , 68.2 )	77.3 ( 58.9 , 88.2 )	73.3 ( 70.9 , 75.5 )	61.6 ( 58.8 , 64.3 )				

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.



Table 19.29 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2002-2008

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	9,811	61.0 ( 59.8 , 62.2 )	78.2 ( 75.5 , 80.7 )	64.6 ( 63.0 , 66.0 )	48.0 ( 45.5 , 50.5 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	1,495	61.2 ( 58.4 , 63.9 )	78.3 ( 74.9 , 81.3 )	45.5 ( 40.9 , 49.9 )	4.3 ( 0.8 , 12.7 )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	8,215	61.3 ( 59.9 , 62.6 )	78.4 ( 73.6 , 82.5 )	67.3 ( 65.7 , 68.8 )	49.4 ( 46.9 , 52.0 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,149	88.7 ( 86.3 , 90.6 )	98.2 ( 87.4 , 99.7 )	92.6 ( 90.4 , 94.3 )	79.1 ( 73.0 , 84.0 )			
2(b) 2.1.1. Mycosis fungoides	2,101	89.8 ( 87.4 , 91.7 )	98.2 ( 87.4 , 99.7 )	93.2 ( 90.9 , 94.8 )	81.3 ( 75.0 , 86.1 )			
2(b) 2.1.2. Sezary syndrome	48	39.6 ( 21.1 , 57.6 )	- ( - , - )	- ( - , - )	29.1 ( 9.4 , 52.5 )			
2(b) 2.2. Peripheral T-cell lymphoma	5,258	53.9 ( 52.2 , 55.6 )	77.6 ( 72.1 , 82.1 )	60.4 ( 58.3 , 62.4 )	41.1 ( 38.1 , 44.1 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	1,793	36.2 ( 33.5 , 39.0 )	63.0 ( 47.7 , 74.9 )	42.1 ( 38.5 , 45.7 )	27.2 ( 23.0 , 31.6 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	581	38.5 ( 33.2 , 43.7 )	- ( - , - )	47.0 ( 39.4 , 54.3 )	31.0 ( 23.9 , 38.3 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	68	56.2 ( 40.5 , 69.3 )	- ( - , - )	57.8 ( 37.2 , 73.9 )	- ( - , - )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,242	55.8 ( 52.6 , 58.9 )	81.0 ( 74.1 , 86.2 )	60.2 ( 56.1 , 64.0 )	32.8 ( 26.5 , 39.1 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	42	18.2 ( 7.7 , 32.1 )	- ( - , - )	24.7 ( 11.0 , 41.3 )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	63	9.7 ( 2.8 , 21.7 )	- ( - , - )	11.8 ( 2.6 , 28.4 )	- ( - , - )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	1,003	78.7 ( 74.6 , 82.1 )	- ( - , - )	84.9 ( 80.5 , 88.3 )	68.2 ( 60.2 , 75.0 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	466	90.6 ( 84.7 , 94.3 )	- ( - , - )	93.3 ( 88.8 , 96.1 )	83.3 ( 68.3 , 91.6 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	168	28.1 ( 20.2 , 36.5 )	- ( - , - )	23.7 ( 13.9 , 35.0 )	29.4 ( 17.4 , 42.4 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	372	34.7 ( 28.6 , 40.9 )	- ( - , - )	33.7 ( 26.8 , 40.8 )	38.6 ( 24.5 , 52.4 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	134	68.9 ( 56.9 , 78.1 )	- ( - , - )	78.5 ( 62.8 , 88.2 )	59.3 ( 40.9 , 73.7 )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	134	15.6 ( 9.0 , 23.9 )	- ( - , - )	15.2 ( 6.9 , 26.3 )	16.4 ( 7.1 , 29.0 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	101	34.7 ( 23.6 , 46.1 )	- ( - , - )	43.5 ( 28.3 , 57.8 )	22.6 ( 8.2 , 41.2 )			
2(c) Non-Hodgkin lymphoma, unknown lineage	3,060	57.9 ( 55.7 , 60.0 )	85.6 ( 82.7 , 88.0 )	54.7 ( 51.1 , 58.2 )	39.3 ( 35.4 , 43.2 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	1,361	64.2 ( 61.3 , 66.9 )	85.9 ( 83.1 , 88.3 )	33.9 ( 28.2 , 39.7 )	19.1 ( 12.7 , 26.5 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	72	35.4 ( 19.9 , 51.3 )	- ( - , - )	58.4 ( 34.0 , 76.4 )	11.8 ( 1.1 , 36.6 )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	1,627	53.1 ( 49.8 , 56.2 )	- ( - , - )	64.9 ( 60.5 , 69.0 )	44.2 ( 39.6 , 48.6 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	9,497	65.1 ( 64.0 , 66.2 )	86.0 ( 85.0 , 87.0 )	34.7 ( 32.6 , 36.7 )	13.2 ( 10.1 , 16.6 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	69	60.2 ( 45.2 , 72.4 )	- ( - , - )	66.8 ( 48.8 , 79.7 )	52.2 ( 28.4 , 71.4 )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	4,685	48.0 ( 46.2 , 49.9 )	80.2 ( 65.3 , 89.2 )	61.0 ( 58.4 , 63.5 )	38.8 ( 36.2 , 41.3 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.30  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2002-2008

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
Lymphoid Neoplasm	89,446	65.9 ( 65.5 , 66.3 )	86.5 ( 85.4 , 87.5 )	72.2 ( 71.7 , 72.7 )	54.9 ( 54.1 , 55.6 )			
1 Hodgkin Lymphoma	7,986	83.7 ( 82.6 , 84.7 )	96.2 ( 94.5 , 97.4 )	87.0 ( 85.9 , 88.0 )	50.6 ( 46.0 , 54.9 )			
2 Non-Hodgkin lymphoma	78,981	64.6 ( 64.1 , 65.0 )	84.3 ( 83.0 , 85.4 )	70.3 ( 69.7 , 70.9 )	55.5 ( 54.7 , 56.3 )			
2(a) Non-Hodgkin lymphoma, B-cell	71,463	65.2 ( 64.7 , 65.6 )	86.3 ( 84.8 , 87.6 )	71.5 ( 70.9 , 72.1 )	56.2 ( 55.4 , 57.1 )			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,655	65.7 ( 63.9 , 67.5 )	86.0 ( 84.3 , 87.6 )	30.8 ( 27.5 , 34.1 )	11.7 ( 6.5 , 18.5 )			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	65,048	65.1 ( 64.6 , 65.6 )	88.0 ( 85.2 , 90.3 )	72.9 ( 72.2 , 73.5 )	56.3 ( 55.5 , 57.2 )			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	16,889	73.5 ( 72.4 , 74.5 )	- ( - , - )	81.9 ( 80.6 , 83.1 )	67.0 ( 65.4 , 68.6 )			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	14,606	76.6 ( 75.5 , 77.7 )	- ( - , - )	85.0 ( 83.6 , 86.2 )	70.3 ( 68.6 , 72.0 )			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	65	40.1 ( 23.2 , 56.4 )	- ( - , - )	- ( - , - )	39.1 ( 18.1 , 59.6 )			
2(a) 2.1.3. Mantle-cell lymphoma	2,218	53.6 ( 50.6 , 56.4 )	- ( - , - )	63.9 ( 59.9 , 67.7 )	44.0 ( 39.7 , 48.3 )			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,518	76.3 ( 72.6 , 79.6 )	- ( - , - )	82.3 ( 77.6 , 86.1 )	72.4 ( 67.2 , 76.9 )			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	638	74.3 ( 68.7 , 79.0 )	- ( - , - )	80.8 ( 73.4 , 86.3 )	69.4 ( 61.1 , 76.2 )			
2(a) 2.2.2. Waldenstrom macroglobulinemia	880	77.6 ( 72.6 , 81.8 )	- ( - , - )	83.4 ( 76.9 , 88.2 )	74.2 ( 67.0 , 80.1 )			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	17,066	59.2 ( 58.3 , 60.2 )	86.5 ( 81.3 , 90.3 )	66.5 ( 65.4 , 67.6 )	49.2 ( 47.5 , 50.8 )			
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	16,917	59.2 ( 58.3 , 60.2 )	86.8 ( 81.7 , 90.6 )	66.5 ( 65.3 , 67.6 )	49.3 ( 47.6 , 50.9 )			
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 2.3.3. Primary effusion lymphoma	45	22.7 ( 10.2 , 38.0 )	- ( - , - )	25.8 ( 12.2 , 41.9 )	- ( - , - )			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	87	83.2 ( 69.6 , 91.1 )	- ( - , - )	91.7 ( 81.2 , 96.4 )	- ( - , - )			
2(a) 2.4. Burkitt lymphoma/leukemia	1,508	57.2 ( 54.4 , 59.9 )	87.6 ( 83.6 , 90.6 )	51.7 ( 48.2 , 55.2 )	28.3 ( 20.4 , 36.7 )			
2(a) 2.5. Marginal-zone lymphoma (MZL)	3,723	87.1 ( 85.0 , 89.0 )	100.0 ( - , - )	90.8 ( 88.7 , 92.5 )	82.5 ( 78.3 , 86.0 )			
2(a) 2.5.1. Splenic MZL	276	85.8 ( 76.5 , 91.7 )	- ( - , - )	88.3 ( 79.4 , 93.5 )	80.7 ( 62.0 , 90.9 )			
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	2,288	90.2 ( 87.4 , 92.5 )	- ( - , - )	92.3 ( 89.7 , 94.3 )	87.1 ( 81.1 , 91.3 )			
2(a) 2.5.3. Nodal MZL	1,159	81.4 ( 77.3 , 84.7 )	- ( - , - )	87.4 ( 83.1 , 90.7 )	74.7 ( 67.5 , 80.6 )			
2(a) 2.6. Follicular lymphoma	8,798	84.2 ( 82.9 , 85.3 )	97.0 ( 79.0 , 99.6 )	87.8 ( 86.5 , 88.9 )	78.2 ( 75.5 , 80.6 )			
2(a) 2.7. Hairy-cell leukemia	1,140	95.2 ( 92.4 , 97.0 )	- ( - , - )	98.0 ( 95.9 , 99.0 )	86.6 ( 76.5 , 92.6 )			
2(a) 2.8. Plasma cell neoplasms	14,387	41.9 ( 40.8 , 43.0 )	- ( - , - )	53.2 ( 51.7 , 54.8 )	32.1 ( 30.6 , 33.6 )			
2(a) 2.8.1. Plasmacytoma	1,036	68.5 ( 64.4 , 72.2 )	- ( - , - )	78.5 ( 74.0 , 82.3 )	51.9 ( 44.4 , 58.8 )			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	13,351	39.8 ( 38.6 , 40.9 )	- ( - , - )	50.5 ( 48.9 , 52.2 )	31.0 ( 29.4 , 32.5 )			
2(a) 2.9. Heavy chain disease	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	2,760	65.1 ( 62.5 , 67.7 )	66.4 ( 43.2 , 81.8 )	71.2 ( 67.9 , 74.2 )	60.5 ( 56.3 , 64.5 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2002-2008

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
2(b) Non-Hodgkin lymphoma, T-cell	5,837	59.6 ( 58.0 , 61.2 )	77.3 ( 74.0 , 80.3 )	61.3 ( 59.3 , 63.2 )	47.5 ( 44.1 , 50.9 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	1,047	62.2 ( 58.8 , 65.4 )	77.8 ( 73.8 , 81.2 )	45.6 ( 40.1 , 51.0 )	0.0 ( - , - )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	4,737	59.3 ( 57.5 , 61.0 )	76.8 ( 70.4 , 82.1 )	63.8 ( 61.6 , 65.8 )	48.8 ( 45.3 , 52.3 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,201	87.2 ( 83.7 , 90.0 )	100.0 ( - , - )	90.5 ( 87.0 , 93.1 )	79.8 ( 71.6 , 85.8 )			
2(b) 2.1.1. Mycosis fungoides	1,173	88.0 ( 84.5 , 90.8 )	100.0 ( - , - )	91.1 ( 87.6 , 93.7 )	81.0 ( 72.6 , 87.0 )			
2(b) 2.1.2. Sezary syndrome	28	47.2 ( 19.0 , 71.2 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2. Peripheral T-cell lymphoma	3,071	52.2 ( 50.0 , 54.4 )	76.1 ( 68.9 , 81.9 )	57.7 ( 55.0 , 60.3 )	38.8 ( 34.7 , 42.9 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	1,059	36.1 ( 32.5 , 39.6 )	66.8 ( 47.9 , 80.1 )	39.2 ( 34.7 , 43.6 )	28.5 ( 22.5 , 34.9 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	303	32.5 ( 25.6 , 39.6 )	- ( - , - )	43.2 ( 33.4 , 52.7 )	21.8 ( 13.0 , 32.0 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	788	54.3 ( 50.2 , 58.1 )	81.4 ( 72.6 , 87.5 )	56.7 ( 51.7 , 61.5 )	29.4 ( 21.3 , 37.9 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	28	14.2 ( 4.0 , 30.5 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	37	0.0 ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	571	77.2 ( 71.6 , 81.8 )	- ( - , - )	86.1 ( 80.2 , 90.4 )	61.2 ( 50.0 , 70.5 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	264	88.9 ( 80.0 , 94.0 )	- ( - , - )	92.4 ( 85.3 , 96.1 )	80.8 ( 60.3 , 91.4 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	88	27.3 ( 17.0 , 38.6 )	- ( - , - )	24.3 ( 12.4 , 38.3 )	24.8 ( 8.6 , 45.4 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	246	35.7 ( 28.5 , 43.0 )	- ( - , - )	33.5 ( 25.7 , 41.5 )	41.2 ( 21.5 , 60.0 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	60	56.2 ( 38.3 , 70.8 )	- ( - , - )	- ( - , - )	44.0 ( 20.3 , 65.6 )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	71	18.4 ( 9.0 , 30.5 )	- ( - , - )	20.4 ( 7.9 , 37.0 )	14.8 ( 3.9 , 32.4 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	53	41.5 ( 25.2 , 57.1 )	- ( - , - )	43.9 ( 21.8 , 64.1 )	- ( - , - )			
2(c) Non-Hodgkin lymphoma, unknown lineage	1,681	57.4 ( 54.4 , 60.2 )	83.5 ( 79.5 , 86.9 )	51.6 ( 47.1 , 55.9 )	38.5 ( 32.6 , 44.4 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	778	64.0 ( 60.2 , 67.6 )	84.1 ( 80.1 , 87.4 )	31.4 ( 24.3 , 38.7 )	24.2 ( 14.0 , 36.0 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	42	27.6 ( 11.3 , 46.7 )	- ( - , - )	- ( - , - )	0.0 ( - , - )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	861	52.2 ( 47.8 , 56.5 )	- ( - , - )	61.6 ( 55.9 , 66.7 )	42.5 ( 35.6 , 49.2 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	5,480	64.9 ( 63.4 , 66.3 )	84.3 ( 82.8 , 85.7 )	34.6 ( 31.9 , 37.3 )	13.8 ( 9.3 , 19.2 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	41	59.6 ( 41.0 , 74.1 )	- ( - , - )	55.9 ( 33.7 , 73.3 )	- ( - , - )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	2,438	48.2 ( 45.6 , 50.7 )	75.9 ( 56.0 , 87.7 )	57.1 ( 53.8 , 60.4 )	39.1 ( 35.2 , 42.9 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.31  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2002-2008

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
Lymphoid Neoplasm	73,767	67.4 ( 66.9 , 67.9 )	89.4 ( 88.3 , 90.5 )	77.9 ( 77.3 , 78.4 )	56.2 ( 55.4 , 56.9 )			
1 Hodgkin Lymphoma	6,747	85.9 ( 84.9 , 86.9 )	95.6 ( 93.6 , 97.0 )	91.3 ( 90.3 , 92.2 )	51.1 ( 47.0 , 55.2 )			
2 Non-Hodgkin lymphoma	64,745	66.1 ( 65.6 , 66.6 )	87.5 ( 86.1 , 88.8 )	75.6 ( 75.0 , 76.2 )	57.1 ( 56.3 , 57.8 )			
2(a) Non-Hodgkin lymphoma, B-cell	59,392	66.5 ( 65.9 , 67.0 )	88.5 ( 86.9 , 89.9 )	76.4 ( 75.7 , 77.1 )	57.8 ( 57.0 , 58.6 )			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	2,986	66.5 ( 64.5 , 68.4 )	89.4 ( 87.7 , 90.9 )	31.4 ( 27.5 , 35.4 )	10.8 ( 6.5 , 16.4 )			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	53,820	66.4 ( 65.8 , 67.0 )	82.5 ( 77.5 , 86.4 )	78.1 ( 77.4 , 78.8 )	57.9 ( 57.1 , 58.7 )			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	11,328	77.6 ( 76.3 , 78.9 )	- ( - , - )	88.5 ( 86.9 , 89.8 )	72.3 ( 70.5 , 74.0 )			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	10,338	79.9 ( 78.6 , 81.2 )	- ( - , - )	90.7 ( 89.2 , 92.1 )	74.7 ( 72.8 , 76.4 )			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	49	35.1 ( 20.1 , 50.5 )	- ( - , - )	- ( - , - )	30.3 ( 13.6 , 49.1 )			
2(a) 2.1.3. Mantle-cell lymphoma	941	54.6 ( 50.1 , 58.9 )	- ( - , - )	67.4 ( 60.5 , 73.4 )	47.5 ( 41.7 , 53.1 )			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,116	75.6 ( 71.3 , 79.3 )	- ( - , - )	84.6 ( 78.8 , 88.9 )	70.5 ( 64.5 , 75.6 )			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	514	75.6 ( 68.9 , 81.1 )	- ( - , - )	82.2 ( 72.5 , 88.7 )	71.9 ( 62.6 , 79.3 )			
2(a) 2.2.2. Waldenstrom macroglobulinemia	602	75.3 ( 69.5 , 80.2 )	- ( - , - )	86.4 ( 78.7 , 91.5 )	69.3 ( 61.1 , 76.0 )			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	14,819	60.8 ( 59.8 , 61.8 )	78.9 ( 71.6 , 84.4 )	73.9 ( 72.6 , 75.1 )	51.2 ( 49.7 , 52.7 )			
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	14,682	60.7 ( 59.6 , 61.7 )	80.2 ( 72.9 , 85.7 )	73.7 ( 72.4 , 75.0 )	51.2 ( 49.7 , 52.7 )			
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 2.3.3. Primary effusion lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	117	83.0 ( 73.1 , 89.5 )	- ( - , - )	86.0 ( 75.5 , 92.2 )	- ( - , - )			
2(a) 2.4. Burkitt lymphoma/leukemia	549	52.5 ( 47.6 , 57.3 )	83.6 ( 74.0 , 90.0 )	55.0 ( 47.9 , 61.5 )	30.9 ( 22.4 , 39.8 )			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,464	90.0 ( 88.2 , 91.5 )	- ( - , - )	95.5 ( 93.9 , 96.8 )	85.0 ( 81.9 , 87.7 )			
2(a) 2.5.1. Splenic MZL	308	85.3 ( 77.0 , 90.7 )	- ( - , - )	93.2 ( 83.5 , 97.3 )	78.7 ( 64.8 , 87.6 )			
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	2,849	93.9 ( 91.7 , 95.5 )	- ( - , - )	98.0 ( 96.0 , 99.0 )	89.7 ( 85.6 , 92.7 )			
2(a) 2.5.3. Nodal MZL	1,307	82.3 ( 78.5 , 85.4 )	- ( - , - )	89.4 ( 85.0 , 92.5 )	77.2 ( 71.8 , 81.7 )			
2(a) 2.6. Follicular lymphoma	8,964	84.9 ( 83.7 , 86.1 )	- ( - , - )	90.7 ( 89.5 , 91.8 )	78.3 ( 76.0 , 80.4 )			
2(a) 2.7. Hairy-cell leukemia	302	92.9 ( 85.8 , 96.6 )	- ( - , - )	96.7 ( 92.3 , 98.6 )	84.3 ( 67.0 , 93.0 )			
2(a) 2.8. Plasma cell neoplasms	12,269	39.8 ( 38.6 , 41.0 )	- ( - , - )	55.0 ( 53.1 , 56.8 )	30.3 ( 28.8 , 31.8 )			
2(a) 2.8.1. Plasmacytoma	626	57.1 ( 51.6 , 62.2 )	- ( - , - )	74.3 ( 67.4 , 79.9 )	40.5 ( 32.6 , 48.1 )			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	11,643	38.9 ( 37.7 , 40.1 )	- ( - , - )	53.6 ( 51.7 , 55.5 )	29.8 ( 28.3 , 31.3 )			
2(a) 2.9. Heavy chain disease	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	2,586	67.7 ( 65.0 , 70.3 )	- ( - , - )	76.2 ( 72.6 , 79.3 )	62.5 ( 58.7 , 66.1 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2002-2008

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	3,974	63.0 ( 61.1 , 64.8 )	80.2 ( 75.1 , 84.4 )	69.4 ( 67.1 , 71.6 )	48.6 ( 45.0 , 52.1 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	448	59.0 ( 53.7 , 64.0 )	80.0 ( 72.9 , 85.4 )	45.1 ( 37.2 , 52.7 )	10.2 ( 2.0 , 26.4 )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	3,478	64.0 ( 62.0 , 66.0 )	81.0 ( 73.3 , 86.7 )	72.3 ( 69.9 , 74.5 )	50.1 ( 46.5 , 53.6 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	948	90.3 ( 87.0 , 92.8 )	96.7 ( 78.5 , 99.5 )	94.9 ( 91.9 , 96.8 )	77.4 ( 67.5 , 84.7 )			
2(b) 2.1.1. Mycosis fungoides	928	91.8 ( 88.5 , 94.1 )	96.7 ( 78.5 , 99.5 )	95.4 ( 92.7 , 97.1 )	81.2 ( 70.8 , 88.2 )			
2(b) 2.1.2. Sezary syndrome	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2. Peripheral T-cell lymphoma	2,187	56.4 ( 53.8 , 58.9 )	80.1 ( 70.8 , 86.7 )	64.6 ( 61.2 , 67.7 )	43.6 ( 39.4 , 47.7 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	734	36.7 ( 32.5 , 40.8 )	- ( - , - )	47.5 ( 41.5 , 53.2 )	25.7 ( 20.0 , 31.7 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	278	45.4 ( 37.6 , 52.8 )	- ( - , - )	51.5 ( 39.3 , 62.4 )	39.5 ( 29.6 , 49.2 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	47	52.4 ( 34.1 , 67.8 )	- ( - , - )	53.0 ( 29.1 , 72.1 )	- ( - , - )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	454	58.3 ( 53.0 , 63.3 )	79.9 ( 66.6 , 88.4 )	66.8 ( 59.8 , 72.8 )	36.6 ( 27.2 , 46.0 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	26	32.7 ( 15.3 , 51.4 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	432	80.4 ( 74.0 , 85.4 )	- ( - , - )	82.8 ( 75.5 , 88.1 )	75.7 ( 63.9 , 84.1 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	202	91.9 ( 84.4 , 95.9 )	- ( - , - )	92.6 ( 82.5 , 97.0 )	84.5 ( 61.7 , 94.3 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	80	28.5 ( 18.0 , 39.9 )	- ( - , - )	26.5 ( 12.2 , 43.2 )	30.8 ( 16.4 , 46.5 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	126	33.2 ( 22.6 , 44.2 )	- ( - , - )	35.3 ( 22.0 , 48.9 )	33.3 ( 15.4 , 52.4 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	74	79.5 ( 65.4 , 88.3 )	- ( - , - )	83.2 ( 65.2 , 92.4 )	73.7 ( 44.4 , 89.1 )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	63	13.3 ( 5.3 , 25.1 )	- ( - , - )	9.2 ( 1.8 , 24.3 )	17.1 ( 4.8 , 35.8 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	48	28.1 ( 14.2 , 43.9 )	- ( - , - )	42.9 ( 23.2 , 61.3 )	- ( - , - )			
2(c) Non-Hodgkin lymphoma, unknown lineage	1,379	58.5 ( 55.2 , 61.7 )	88.4 ( 84.3 , 91.5 )	60.1 ( 54.1 , 65.6 )	40.0 ( 34.8 , 45.2 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	583	64.2 ( 59.8 , 68.2 )	88.4 ( 84.3 , 91.5 )	37.7 ( 28.5 , 46.9 )	14.4 ( 7.2 , 23.9 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	30	51.4 ( 24.4 , 73.0 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	766	53.9 ( 49.0 , 58.5 )	- ( - , - )	71.0 ( 63.4 , 77.3 )	45.5 ( 39.4 , 51.5 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	4,017	65.4 ( 63.7 , 67.0 )	88.5 ( 86.9 , 89.9 )	34.8 ( 31.5 , 38.1 )	12.1 ( 8.3 , 16.6 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	28	60.4 ( 36.5 , 77.8 )	- ( - , - )	- ( - , - )	- ( - , - )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	2,247	47.9 ( 45.2 , 50.5 )	- ( - , - )	67.0 ( 62.8 , 70.8 )	38.5 ( 35.1 , 41.8 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

# SEER Observed Incidence, SEER Delay Adjusted Incidence and US Death Rates<sup>a</sup> Non-Hodgkin Lymphoma, by Race and Sex




Figure 19.1

<sup>a</sup> Source: SEER 9 areas and US Mortality Files (National Center for Health Statistics, CDC). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines and APCs are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.  
\* The APC is significantly different from zero ( $p < 0.05$ ).

# SEER Incidence and US Death Rates<sup>a</sup> Non-Hodgkin Lymphoma, Both Sexes

Joinpoint Analyses for Whites and Blacks from 1975-2009  
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2009




Figure 19.2

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

<sup>a</sup> Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2009 period allow a maximum of 5 joinpoints. Analyses for other ethnic groups during the period 1992-2009 allow a maximum of 3 joinpoints.


<sup>b</sup> API = Asian/Pacific Islander.

<sup>c</sup> AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>d</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, South Carolina, Oklahoma, and Vermont.

Figure 19.3

# Non-Hodgkin Lymphoma Incidence Rates, 1980 vs 2009 Males by Age at Diagnosis and SEER area



Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103).



# Non-Hodgkin Lymphoma SEER Incidence by Age 1975-1977 VS 2007-2009 All Races, Males




Figure 19.4

Source: SEER 9 areas. Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103).

# SEER Observed Incidence and SEER Delay Adjusted Incidence Rates<sup>a</sup> SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Male, by Race




Figure 19.5

<sup>a</sup> Source: SEER 9 areas and SEER 13 areas.  
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).  
Regression lines and APCs are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.  
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.  
\* The APC is significantly different from zero ( $p < 0.05$ ).

# SEER Observed Incidence and SEER Delay Adjusted Incidence Rates<sup>a</sup> SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Female, by Race




Figure 19.6


<sup>a</sup> Source: SEER 9 areas and SEER 13 areas.  
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).  
Regression lines and APCs are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.  
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.  
\* The APC is significantly different from zero ( $p < 0.05$ ).

Figure 19.7

## Non-Hodgkin Lymphoma

### 5-Year SEER Conditional Relative Survival and 95% Confidence Intervals

Probability of surviving the next 5 years given the cohort  
has already survived 0, 1, or 3 years  
1998-2008 by stage at diagnosis



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG contribute cases for diagnosis years 2000-2008. The remaining 13 SEER Areas contribute cases for the entire period 1998-2008.

Percent surviving is not shown if based on less than 25 cases.

Confidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error.